

Appl. No. : 10/646,075  
Filed : August 22, 2003

### REMARKS

Claims 32-35 and 69-70 are currently pending. Applicants thank the Examiner for the review of the instant application, and for withdrawing the rejection of Claims 32-35 under the judicially created doctrine of obviousness-type double patenting. Applicants appreciate the indication that the Examiner believes Claim 70 is in condition for allowance. The rejections of the remainder of the presently pending claims are respectfully traversed.

#### **Rejection Under 35 U.S.C. §103(a)**

The Examiner has maintained the rejection of Claims 32-35, and has rejected Claim 69 as allegedly being unpatentably obvious over McCarty et al (US Patent No. 5,707, 970; "McCarty") in view of Speck (US Patent No. 6,006,659; "Speck"), Harrison's Principles of Internal Medicine ("Harrison's") and Levere (US Patent No. 5,217, 997; "Levere"). Regarding Claim 69, the Examiner argues that McCarty teaches that arginine is a precursor for nitric oxide, and that nitric oxide exerts vasodilatory effects. The Examiner then concludes that since arginine is present in the arginine silicate complex, it would have been obvious that the arginine silicate complex would provide an increase in vascular relaxation. Regarding Claims 32-35, the Examiner maintains the following: (1) McCarty teaches that arginine teaches administration of arginine silicate inositol for the treatment of atherosclerosis or as a supply of arginine; (2) Speck teaches that atherosclerosis is a disease of the coronary vascular system, and thus treatment of atherosclerosis with arginine silicate inositol would treat diseases secondary to atherosclerosis; (3) Speck teaches atherosclerosis can lead to reduced perfusion into the extremities or brain infarct, which the Examiner alleges involves microvascular/macrovascular complications, thus treatment of atherosclerosis with arginine silicate inositol would treat diseases secondary to coronary vascular disease; (4) Harrison's teaches that a major goal of therapy for nephrosclerosis is control of hypertension, Levere teaches arginine for the treatment of hypertension, and McCarty teaches arginine silicate inositol for the supply of arginine, and thus it would be obvious to treat nephrosclerosis with arginine silicate inositol.

Applicants respectfully disagree.

To establish a *prima facie* case of obviousness a three-prong test must be met. First, there must be some suggestion or motivation, either in the references or in the knowledge generally available among those of ordinary skill in the art, to modify the reference. Second, there must be

Appl. No. : 10/646,075  
Filed : August 22, 2003

a reasonable expectation of success found in the prior art. Third, the prior art must reference must teach or suggest all the claim limitations. *In re Vaeck*, 947 F.2d 488 (Fed. Cir. 1991

*The teachings of McCarty do Not Render Claims 32-35 Obvious in view of Speck*

a. McCarty and Speck Do Not Teach or Suggest Arginine Silicate Inositol for Treating Disease Secondary to Coronary Vascular Disease

Applicants submit that the teachings of McCarty and Speck cannot support a prima facie case of obviousness for Claims 32-35. The Examiner argues that because McCarty teaches administration of arginine silicate inositol for the treatment of atherosclerosis, and Speck teaches that “atherosclerosis *can* lead to reduced perfusion into the extremities or brain infarct” (Office Action, Oct. 8, 2004, p. 4), that the skilled artisan would appreciate that administration of arginine silicate inositol per the teachings of McCarty would “could. . . [prevent those diseases secondary to atherosclerosis] from occurring or else effectively ameliorate[] [them].” *Id.* Applicants submit, and the Examiner has acknowledged, that McCarty does not teach arginine silicate inositol for “*treating a disease secondary to coronary vascular disease.*” *Id. at 3.* (Emphasis added) In essence, the Examiner asserts that the usefulness of a compound (i.e., arginine silicate inositol) for the treatment of one type of primary coronary vascular disease (i.e., atherosclerosis) renders that compound useful for the treatment of a variety of conditions, merely because a subset of those conditions may arise as a consequence of atherosclerosis. While the treatment of atherosclerosis may *prevent the emergence* of some types of diseases secondary to atherosclerosis, Applicants submit that nothing in McCarty and Speck suggests the same treatment (administration of arginine inositol silicate) used for treating atherosclerosis, as described in McCarty, would “effectively ameliorate” diseases secondary to atherosclerosis, or coronary vascular disease in general. Further, the Examiner has provided no support for the conclusion that arginine silicate inositol could “effectively ameliorate” any of the above conditions. In short, at most, McCarty and Speck teach a treatment that may prevent the worsening of conditions that may arise as secondary to atherosclerosis. Applicants submit that this is not the same as treating those diseases, and that nothing in McCarty and Speck teaches or suggests arginine silicate inositol is useful in *treating* diseases secondary to coronary vascular disease.

McCarty describes atherosclerosis as “a complex and chronic disease involving the gradual accumulation of lipids, collagen, elastic fibers and proteoglycans in the arterial wall.”

Appl. No. : 10/646,075  
Filed : August 22, 2003

Col. 1, lines 10-12. According to the Examiner, Speck discusses “reduced perfusion into the extremities” and “brain infarct,” which are microvascular/macrovacular complications. (Office Action, Oct. 8, 2004, p. 4) Applicants submit that those skilled in the art would not find it obvious that a treatment directed to accumulation of lipids, collagen, elastic fibers and proteoglycans in the arterial walls would be useful for treating “reduced perfusion into the extremities,” particularly where the reduced perfusion to the extremities is caused by something other than atherosclerosis, e.g., vasoconstriction. In instances where reduced perfusion to the extremities arises from something other than atherosclerosis, the treatment would not logically involve treatments aimed at curing atherosclerosis. Likewise, one skilled in the art would not necessarily find it obvious that a treatment directed to atherosclerosis would be useful for treating brain infarct.

Given the above, Applicants submit that McCarty and Speck fail to provide suggestion or motivation to treat diseases secondary to coronary vascular disease with arginine silicate inositol, and that these references do not render Claims 32-35 obvious.

b. McCarty and Speck Provide No Reasonable Expectation That Arginine Silicate Inositol Will Successfully Treat Disease Secondary to Coronary Vascular Disease

As discussed above, the PTO must show that the references relied upon for a rejection under 35 U.S.C. § 103(a) must lead one of ordinary skill in the art to believe that he or she would have a reasonable expectation of success in practicing the claimed invention in view of the cited art. See, In re Merck & Co., Inc., 231 U.S.P.Q. 375 (Fed. Cir. 1986); M.P.E.P. §2143.02. Applicants respectfully submit that there is no reasonable expectation of success in *treating* diseases secondary to coronary vascular disease, such as nephrosclerosis, abnormal liver lipid concentrations, microvascular complications, and macrovascular complications provided in McCarty and Speck. While McCarty and Speck may discuss treatment of atherosclerosis, the references are completely silent as to whether arginine silicate inositol would be efficacious in the *treatment* of diseases secondary to coronary vascular disease. Applicants agree that the treatment of atherosclerosis may be useful in *preventing* the onset or occurrence of diseases that arise as a result of atherosclerosis, but submit that this is not the same as treating those diseases themselves. Because the references provide no expectation of success in reversing or ameliorating diseases secondary to coronary vascular disease, they cannot form the basis of a rejection under 35 U.S.C. § 103(a).

Appl. No. : 10/646,075  
Filed : August 22, 2003

The teachings of McCarty do Not Render Claims 32-35 Obvious in view of Harrison's and Levere

a. McCarty, Harrison's and Levere Do Not Teach or Suggest Arginine Silicate Inositol for Treating Disease Secondary to Coronary Vascular Disease

Applicants submit that the teachings of McCarty, Harrison's and Levere cannot support a *prima facie* case of obviousness for Claims 32-35. The Examiner argues that Claim 32 reads on nephrosclerosis, and that Harrison's teaches that a major goal in the treatment of nephrosclerosis is the control of hypertension. According to the Examiner, Levere and McCarty teach that arginine is useful in the control of hypertension, and that arginine silicate inositol is a good source of arginine. From the above, the Examiner arrives at the conclusion that it would have been obvious to one skilled in the art that arginine silicate inositol is useful in treating diseases secondary to coronary vascular disease. Nephrosclerosis is a disease characterized by hardening of the kidneys. Applicants submit that given the cited references, one skilled in the art would not find it obvious that a compound (i.e., arginine silicate inositol) useful for treating hypertension would be useful in *treating* nephrosclerosis, particularly in light of the fact that nephrosclerosis does not necessarily arise as a result of hypertension. See, e.g., Fervenza, F., "Nephrosclerosis," from <<http://www.emedicine.com/med/topic1611.htm>>, p. 2, last visited April 6, 2005, attached herewith as Exhibit 1. (Reporting that the term "the pathologic changes [associated with nephrosclerosis] are also observed in kidney biopsy specimens of patients who are normotensive, particularly those of advanced age or with diabetes."); Bos, W. et al., (2001) "Renal Vascular Changes in Renal Disease Independent of Hypertension," *Nephrol. Dial. Transplant*, 16: 537-541, attached herewith as Exhibit 2. It is clear from the above that one skilled in the art would not find it obvious that a compound useful in the control of hypertension will be useful in the treatment of nephrosclerosis, or any other disease. It is *not* evident from Harrison's, McCarty, and Levere, that administration of arginine silicate inositol would have any effect on reversing or *treating* nephrosclerosis, particularly in patients who have nephrosclerosis but are normotensive. As such, Applicants submit that the above references do not establish render Claims 32-35 obvious.

b. McCarty, Harrison's and Levere Provide No Reasonable Expectation That Arginine Silicate Inositol Will Successfully Treat Disease Secondary to Coronary Vascular Disease

Appl. No. : 10/646,075  
Filed : August 22, 2003

McCarty, Harrison's and Levere would not lead one of ordinary skill in the art to believe that he or she would have a reasonable expectation of success in practicing the claimed invention in view of the cited art, as required to form the basis for a rejection under 35 U.S.C. § 103(a). McCarty discloses treatment of hypertension with arginine. However, based on the discussion above, one skilled in the art would not expect that a compound useful for treating hypertension would also be useful for treating or alleviating nephrosclerosis. Applicants submit that the treatment of atherosclerosis may be at most useful in *preventing* the onset or occurrence of diseases that arise as a result of atherosclerosis, including nephrosclerosis, but further submit that this is not the same as treating those diseases themselves. Because the references provide no expectation of success, they cannot form the basis of a rejection under 35 U.S.C. § 103(a).

### CONCLUSION

In view of the foregoing arguments, Applicants respectfully submit that the present application is in condition for allowance. Nevertheless, the PTO is invited to contact the undersigned at the telephone number appearing below to discuss any remaining issues.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: \_\_\_\_\_

Apr. 6, 2005

By: \_\_\_\_\_



Ned A. Israelsen  
Registration No. 29,655  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

## EXHIBIT 1



(advertisement)

Search


[Home](#) | [Specialties](#) | [Resource Centers](#) | [CME](#) | [PDA](#) | [Contributor Recruitment](#) | [A](#)

☐ Articles ☐ Images ☐ CME ☐ Patient Education ☒ Advanced Search ☒ Consumer Health [Link](#)
[Back to: eMedicine Specialties > Medicine, Ob/Gyn, Psychiatry, and Surgery > Nephrology](#)

## Nephrosclerosis

[Rate this Article](#)
[Email to a Colleague](#)
**Last Updated:** September 28, 2004

**Synonyms and related keywords:** HN, hypertension, hypertensive nephrosclerosis, hypertensive nephropathy, nephroangiosclerosis, end-stage renal disease, ESRD, end stage renal disease, end-stage kidney disease, end stage kidney disease, hypertensive retinopathy, left ventricular hypertrophy, minimal proteinuria, progressive renal insufficiency, benign nephrosclerosis, nephroangiosclerosis, blood pressure control, BP control

AUTHOR INFORMATION	Section 1 of 11	Next
<a href="#">Author Information</a> <a href="#">Introduction</a> <a href="#">Clinical Differentials</a> <a href="#">Workup</a> <a href="#">Treatment</a> <a href="#">Medication</a> <a href="#">Follow-up</a> <a href="#">Miscellaneous</a> <a href="#">Pictures</a> <a href="#">Bibliography</a>		

**Author:** Fernando Fervenza, MD, PhD, Associate Professor, Mayo Clinic College of Medicine; Consultant, Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic

**Coauthor(s):** Stephen C Textor, MD, Professor of Medicine, Mayo Clinical College of Medicine; Consultant, Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic; Participating Author, Joint National Commission Guidelines VI

Fernando Fervenza, MD, PhD, is a member of the following medical societies: American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society of Nephrology, International Society of Nephrology, and National Kidney Foundation

**Editor(s):** Chike Magnus Nzerue, MD, Associate Professor, Director of Nephrology Fellowship Program, Department of Internal Medicine, Division of Nephrology, University of Rochester School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, Pharmacy, eMedicine; Eleanor Lederer, MD, Director, Outpatient Clinics and Nephrology Fellowship Program, Professor of Medicine, Department of Internal Medicine, Division of Nephrology, University of Louisville School of Medicine; Rebecca J Schmidt, DO, FACP, Associate Professor of Medicine, Chief, Section of Nephrology, Department of Medicine, West Virginia University School of Medicine; and Vecihi Batuman, MD, FACP, Chief of Renal-Hypertension Section, New Orleans Veterans Affairs Medical Center; Professor, Department of Internal Medicine, Section of Nephrology, Tulane University School of Medicine

### Hypertension Resources

[Hypertension Resources](#)
[View all Hypertension Articles](#)
[Hypertension](#)
[Hypertension Multimedia](#)

### Quick Links

[Author Information](#)  
[Introduction](#)  
[Clinical Differentials](#)  
[Workup](#)  
[Treatment](#)  
[Medication](#)  
[Follow-up](#)  
[Miscellaneous](#)  
[Pictures](#)  
[Bibliography](#)
[Click for images.](#)
[Related](#)
[Continuing Education](#)
[CME available](#)

## INTRODUCTION

Section 2 of 11 [Back Top Next]

Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Pictures Bibliography

this topic  
here to t  
CME.

Patient

Click  
patient

**Background:** According to the 2003 US Renal Data System (USRDS), hypertensive nephrosclerosis (HN) accounts for at least 26 % of patients reaching end-stage renal disease (ESRD) each year in the United States. HN is the second most common cause of ESRD in white people (24%) and is the leading cause of ESRD in black people (33%).

The term HN has traditionally been used to describe a clinical syndrome characterized by long-term essential hypertension, hypertensive retinopathy, left ventricular hypertrophy, minimal proteinuria, and progressive renal insufficiency. Most cases are diagnosed based solely on clinical findings. In fact, most of the literature dedicated to HN is based on the assumption that progressive renal failure in a patient with long-standing hypertension, moderate proteinuria, and no evidence suggesting an alternative diagnosis characterizes HN. The lack of firm criteria on which to base a histologic diagnosis and the lack of a clear demonstration that hypertension initiates the development of renal failure likely indicate that the true prevalence of HN has been overestimated.

As reported by Zuccalà and Zucchelli (1996), part of the confusion in the classification of HN stems from the use of the word nephrosclerosis. Coined almost a century ago by Theodor Fahr, nephrosclerosis simply means hardening of the kidney. In the United States and Europe, the terms HN, benign nephrosclerosis, and nephroangiosclerosis are commonly used to describe the same clinical condition. These terms refer more to the pathologic changes attributed to the effects of hypertension than to the clinical picture of the disease in question. Unfortunately, the pathologic changes are not specific to hypertensive renal injury; they are also observed in kidney biopsy specimens of patients who are normotensive, particularly those of advanced age or with diabetes.

A couple of important points have been made in recent studies. First, among an unselected sample of community-based participants in the Framingham Heart Study, the combination of hypertension and a mild reduction in the glomerular filtration rate (GFR) was found to be an important risk factor for the development of new-onset kidney disease. Other factors noted were diabetes, obesity, smoking, and a low high-density lipoprotein cholesterol level. Second, systolic BP is a strong, independent predictor of a decline in kidney function among older persons with isolated systolic hypertension. This is a significant finding because most cases of uncontrolled hypertension in the United States are due to systolic hypertension among older adults.

Most patients reaching ESRD from any cause are hypertensive, with nephrosclerosis being the classic finding in end-stage kidneys. Regardless of the etiology, once hypertension develops, a cycle of renal injury, nephrosclerosis, worsening of hypertension, and further renal injury is established. As a result, in a patient presenting with ESRD, determining whether nephrosclerosis is the cause or the consequence of chronic renal injury may be difficult.



**Pathophysiology:** Two pathophysiologic mechanisms have been proposed for the development of HN. One mechanism suggests that glomerular ischemia causes HN. This occurs as a consequence of chronic hypertension resulting in narrowing of preglomerular arteries and arterioles, with a consequent reduction in glomerular blood flow. Alternatively, glomerulosclerosis occurs because of glomerular hypertension and glomerular hyperfiltration. According to this theory, hypertension causes some glomeruli to become sclerotic. As an attempt to compensate for the loss of renal function, the remaining nephrons undergo vasodilation of the preglomerular arterioles and experience an increase in renal blood flow and glomerular filtration. The result is glomerular hypertension, glomerular hyperfiltration, and progressive glomerular sclerosis. These mechanisms are not mutually exclusive, and they may operate simultaneously in the kidney.

Furthermore, Tracy and Ishii (2000) postulate that nephrosclerosis may not be a single disease entity in the sense of responding to a single etiology such as hypertension or aging. Rather, nephrosclerosis appears to be multifactorial. It may, in part, be a consequence of fibroplasias in microscopic arteries causing ischemic damage to some nephrons; however, it also may be the end product of a mixture of converging separate pathologic conditions, ie, "second hits," of which only some are known.

Genetically mediated animal models of hypertension, including the Dahl rat and the spontaneous hypertensive rat (SHR), have been used to investigate the role of hypertension in the development of nephrosclerosis. Fundamental differences exist among the strains and between rat and human hypertension. The SHR most closely resembles human essential hypertension. The SHR becomes hypertensive without exposure to salt. Micropuncture studies in hypertensive rats demonstrate an increased preglomerular vasoconstriction that is effective in preventing the development of intraglomerular hypertension. In fact, the SHR develops little renal damage, unless uninephrectomized. In these animals, rigorous BP control does not prevent the development of proteinuria and the pathologic changes of HN. The Dahl salt-sensitive rat develops proteinuria before hypertension and before a high-sodium diet is administered. Of note, no glomerular hypertension occurs.

In patients with essential hypertension, hemodynamic studies frequently show a reduction in renal blood flow. The increased preglomerular vasoconstriction of the afferent arteriole and interlobular artery is thought, at least initially, to exert a protective effect in the glomerulus. With time, sclerosis of the preglomerular vessels causes further reduction in renal blood flow. The GFR is maintained because of increased intraglomerular pressure secondary to efferent arteriolar vasoconstriction and systemic hypertension. Eventually, glomerular ischemia and tubular ischemia develop. Considered together, these data suggest that hypertension precedes and accelerates arteriolar changes in the renal vessels.

## Genetics

A genetic link for hypertension and related renal failure is supported by studies demonstrating familial clustering of HN in black people and, to the same extent, in white people. The idea of a genetic predisposition to renal injury in black people is



also supported by reports of clinical trials.

In the Multiple Risk Factor Intervention Trial (MRFIT), no changes in the reciprocal creatinine slope were observed in white people, but a significant loss in kidney function was observed in black people despite similar levels of BP control. Similarly, secondary analyses from the Modification of Diet in Renal Diseases (MDRD) study demonstrated that at equivalent mean arterial pressures greater than 98 mm Hg, black patients had a reduction in their GFR at a rate of approximately 1 mL/min/y more than white patients. These observations have led to investigations into genetic factors predisposing to renal damage.

In different populations, the *DD* genotype is associated with a higher prevalence of progressive renal disease. This genotype is more common in the black population than the white population. Black people with hypertension also have increased angiotensinogen mutations compared with white people with hypertension. Homozygous D polymorphism is associated with an enhanced pressor response to angiotensin I. In patients with immunoglobulin A nephropathy, homozygous D polymorphism appears to influence the rate of progression of renal diseases and the response to ACE inhibitors; thus, ACE polymorphism could be an important modulator for the renal response to injury and the response to treatment in persons with HN. Whether these data are also applicable to the black population remains to be determined.

#### Frequency:

- **In the US:** Over the last 2 decades, ESRD attributed to HN has contributed significantly to the 7-11% per year increase in new patients starting dialysis in the United States. According to the 2003 USRDS, rates of ESRD caused by hypertension increased almost 50%, while the increase was 11% for glomerulonephritis and 21% for cystic kidney disease. When patients are separated according to race, hypertension is the leading cause of ESRD in black people, accounting for 34% of patients initiating dialysis during this period.
- **Internationally:** In Europe, according to the European Dialysis and Transplant Association registry, HN is a less common cause of ESRD, accounting for 12% of new patients starting renal replacement therapy. However, the reported prevalence varies among different countries, with France and Italy reporting HN as being responsible for ESRD in 21% and 27% of patients starting dialysis, respectively. In Asia, hypertension appears to be a relatively infrequent cause of ESRD, with both Japanese and Chinese registries reporting 6% and 7%, respectively. Establishing whether these differences are real or reflect differences in accuracy of diagnosis or criteria for diagnosis in different countries is difficult.

**Mortality/Morbidity:** According to the 2003 USRDS, the annual mortality rate for patients on hemodialysis in the United States is 23.3%. HN accounts for more than one third of patients on hemodialysis.

**Race:** Marked differences exist in the prevalence of HN among patients of different ethnic backgrounds. Although black people make up 12% of the US population, they account for 28% of the patients on renal replacement therapy. With perhaps the exception of atherosclerotic renal disease, black people are at an increased risk of renal diseases from any cause, especially HN. In black people, HN occurs earlier, is more severe, and more often causes ESRD (36.8% in black patients vs 26% in white patients).

- In persons of all age groups, ESRD is more common in black people. The increased susceptibility of black patients with hypertension to develop progressive renal failure cannot be explained solely by the higher prevalence of hypertension, severity of hypertension, or socioeconomic factors. The MRFIT indicated that effective BP control was associated with stable renal function in white people but not in black people. Socioeconomic differences alone among races do not explain the higher prevalence of HN in black people because stroke and cardiovascular mortality rates have decreased equally in both white and black populations.
- Several renal, hormonal, and physiologic differences, including increased BP sensitivity to a high-salt diet, increased renal vascular resistance, and decreased renal blood flow, are suggested as an explanation for the susceptibility of black people to HN. A decreased nephron number secondary to low birth weight, which is more common in black people, is also suggested to be a part of the increased risk for progressive renal failure in this patient population. In addition, renal angiograms of black patients with hypertension and normal renal function show increased tortuosity and occlusion in the interlobular and arcuate arteries compared with those of white patients with similar BPs and renal function.

**Age:** The diagnosis of HN increases with advancing age. The peak age for the development of ESRD in white patients is 65 years and older, while the peak age is 45-65 years in black people. In most cases, the diagnosis of HN in older patients is made clinically because of the reluctance to perform a renal biopsy in this elderly population. Even when a renal biopsy specimen is available, distinguishing vascular lesions due to aging from those due to hypertension may be difficult. In this respect, atheromatous renal vascular disease has been increasingly recognized as a common finding in patients older than 50 years.

- Rimmer and Gennari (1993) estimate that atheromatous renal vascular disease accounts for 5-15% of all patients who develop ESRD each year. In addition, cholesterol embolism resulting from atheromatous plaque disruption with subsequent shedding of cholesterol crystals into the renal circulation is frequently diagnosed in this patient population. Both renal artery stenosis and cholesterol embolism are associated with renal microvascular lesions and with glomerular sclerosis. Neither of these findings should be underestimated because patients older than 65 years represent at least 45% of the total population of patients on dialysis in the United States.
- Similarly, Appel et al (1995) found bilateral renal artery stenoses in 11% of

patients on hemodialysis who are older than 50 years. After extrapolating their results to the total number of cases of ESRD, multiplying by the number of patients aged 50 years or older, and multiplying by the number of patients with ischemic renal disease, Appel et al concluded that more than 3500 cases of ischemic renal disease remain undiagnosed each year in the United States. If these predictions are correct, ischemic renal disease is likely the fourth most common cause of ESRD in patients older than 50 years.

- More recently, Hansen et al (2002) provided the first population-based estimate of the prevalence of renovascular disease among free-living elderly American participants of the Cardiovascular Health Study (CHS). This is a multicenter, longitudinal cohort study of cardiovascular disease risk factors, morbidity, and mortality among free-living adults older than 65 years. CHS participants numbered 870, and each underwent renal duplex sonography to assess for the presence or absence of renovascular disease, defined as greater than or equal to 60% diameter-reducing renal artery stenosis or occlusion. The results of this study show that renovascular disease is present in 6.8% of all individuals, regardless of race (6.9% of white participants and 6.7% of black participants).

<b>CLINICAL</b>	<b>Section 3 of 11</b> <a href="#">[Back</a> <a href="#">Top</a> <a href="#">Next]</a>
<a href="#">Author Information</a> <a href="#">Introduction</a> <a href="#">Clinical</a> <a href="#">Differentials</a> <a href="#">Workup</a> <a href="#">Treatment</a> <a href="#">Medication</a> <a href="#">Follow-up</a> <a href="#">Miscellaneous</a> <a href="#">Pictures</a> <a href="#">Bibliography</a>	

**History:** Patients may present with hypertension, its complications (eg, heart failure, stroke), and/or symptoms of uremia. In most patients, hypertension is present for many years (usually >10 y), with evidence of periods of accelerated or poorly controlled BP. Features suggesting the diagnosis of HN are as follows:

- Black race
- Hypertensive retinal changes
- Left ventricular hypertrophy
- Long-standing or very severe hypertension
- Proteinuria less than 0.5 g/d
- Hypertension diagnosed prior to the onset of proteinuria
- Hypertension preceding renal dysfunction
- No evidence of another renal disease
- Biopsy findings compatible with the diagnosis

**Physical:** Upon physical examination, evidence of hypertension-related target

organ damage includes hypertensive changes in the retinal vessels and signs of left ventricular hypertrophy. Hemorrhages or exudates are characteristic of accelerated hypertension, and papilledema is a feature of malignant hypertension.

**Causes:** No causes for HN are known. See [Pathophysiology](#). A gene that predisposes to hypertensive renal injury has been identified in rats. To date, however, no specific hypertensive ESRD-associated gene has been identified in humans. Correct identification of HN susceptibility genes requires accurate HN phenotyping. The major impediment to establishing a reliable HN phenotype is the absence of strong clinical criteria to distinguish HN from other renal diseases. Genetic approaches to HN require careful scrutiny of clinical diagnoses before assigning phenotypes to study subjects.

<b>DIFFERENTIALS</b>	<b>Section 4 of 11</b> <a href="#">[Back Top Next]</a>
<a href="#">Author Information</a> <a href="#">Introduction</a> <a href="#">Clinical</a> <a href="#">Differentials</a> <a href="#">Workup</a> <a href="#">Treatment</a> <a href="#">Medication</a> <a href="#">Follow-up</a> <a href="#">Miscellaneous</a> <a href="#">Pictures</a> <a href="#">Bibliography</a>	

### Other Problems to be Considered:

- Renal atherosclerotic disease
- Cholesterol microembolization
- Malignant hypertension
- Mildly active primary renal disease

### Hypertension and atherosclerotic renal artery disease

Hypertension is frequently associated with atheromatous renal artery disease (RAS), especially in elderly patients. Atherosclerotic RAS is present in 7% of the general population older than 65 years (regardless of race) and in 20-45% of patients older than 50 years who have had an angiography performed because of peripheral or coronary disease.

The predominant clinical manifestations of atherosclerotic RAS include hypertension, renal failure (ischemic nephropathy), recurrent episodes of congestive heart failure, and flash pulmonary edema. Sudden worsening of renal function in a patient who is hypertensive and who was started on an ACE inhibitor is also suggestive of renal vascular disease.

Not all patients with RAS are hypertensive. Olin et al (2002) studied 395 consecutive patients who had undergone arteriography as part of an evaluation for aortoiliac or peripheral vascular disease and who did not have the usual clues to suggest RAS and found greater than or equal to 50% stenosis in approximately 35% of nondiabetic patients and in up to approximately 50% of diabetic patients.

Goals for identifying RAS include improving BP control and preserving renal function. The diagnosis of RAS can be established with the use of Doppler ultrasound scanning, magnetic resonance angiography using gadolinium as the contrast agent, or renal arteriography. Most patients are treated medically, but

when progressive hypertension, renal insufficiency, or circulatory congestion develops, renal revascularization should be considered. Renal revascularization (ie, percutaneous transluminal angioplasty/stent, surgery) may result in improvement in BP control in 50-80% of patients, but cure is unusual in patients with long-standing hypertension. Vascular intervention (percutaneous transluminal angioplasty or surgery) may also improve or stabilize renal function in selected patients.

The complication rate for renal artery stenting varies considerably between centers, and complications include hematomas, retroperitoneal hemorrhage, arterial dissections, pseudoaneurysm formation, arteriovenous fistula, rupture of the renal artery, vessel occlusion, or infection. Restenosis occurs in 14-20% of cases. In addition, patients may develop contrast-induced acute renal failure and cholesterol embolism. As a result, approximately 20% of patients who undergo vascular intervention experience a worsening of renal function or develop ESRD; additionally, BP is not improved in 20-50% of patients.

To date, no randomized trial has shown a survival benefit for either endovascular or surgical revascularization compared with medical management. Recognizing RAS and identifying patients who will benefit from revascularization remains a significant challenge for clinicians. For a review on this subject, see the 2003 article by S.C. Textor.

### Cholesterol microembolization

Besides renal artery stenosis, cholesterol microembolization can also mimic HN. Cholesterol embolization is frequently found at autopsy in white patients older than 50 years, at a rate varying from 4.7-17.7%. This condition is also observed in black patients; it was present in 2 of 39 patients in the African American Study of Kidney Disease and Hypertension (AASK). Making the diagnosis is not difficult when patients present acutely following an angiographic procedure, transluminal angioplasty, or anticoagulant treatment or as a complication of vascular surgery. However, in many cases, the disease is chronic, patients are relatively asymptomatic, and, presumably, the disease is the result of a spontaneous renal cholesterol embolism. These patients may present with nephrotic-range proteinuria. Renal biopsy specimens show classic needle-shaped crystals in the glomeruli or renal arteries.

### Renal biopsy findings

Renal biopsy findings that mimic HN can be observed in various clinical conditions, even in the absence of hypertension. These conditions include hemolytic uremic syndrome, postpartum renal failure, scleroderma, chronic radiation nephritis, and obesity. Reaching an accurate diagnosis can be difficult in patients presenting late in the course of renal failure.

WORKUP	Section 5 of 11 <a href="#">Back</a>
<a href="#">Author Information</a> <a href="#">Introduction</a> <a href="#">Clinical</a> <a href="#">Differentials</a> <a href="#">Workup</a> <a href="#">Treatment</a> <a href="#">Medication</a> <a href="#">Follow-up</a> <a href="#">Miscellaneous</a> <a href="#">Pictures</a> <a href="#">Bibliography</a>	

**Lab Studies:**

- Laboratory evaluation includes the following:
  - Baseline complete blood cell count
  - Creatinine level
  - Electrolyte status
  - Urinalysis
  - Either a spot urine test for albumin or creatinine ratio or a 24-hour urine collection - determine total protein excretion
- In a large series of patients, most had urine protein excretion of lower than 1 g/d; however, patients with biopsy-proven HN, a 24-hour urinary protein excretion greater than 1 g/d was described. When secondary changes of focal segmental glomerulosclerosis (FSGS) related to hyperfiltration develop, proteinuria can increase to the nephrotic range.
- Innes et al (1993) reviewed 185 cases of patients with renal biopsy specimens that were solely as HN. In 40% of these patients, urinary protein excretion was greater than 1.5 g/c, with some excreting more than 3 g/d and 18% having serum albumin values less than 3 g/dL. Similar findings were reported by Harvey et al (1992). Freedman et al (1994) questioned these findings because many biopsy specimens showed segmental and diffuse glomerulosclerosis. Harvey et al attributed these lesions to the effect of hypertension, but Freedman et al felt that these patients had FSGS, not HN.
- The contrasting conclusions of Harvey et al and Freedman et al highlight the problems of distinguishing HN from primary glomerular disease purely on clinical grounds. Nevertheless, in black people who are hypertensive, do not have diabetes, and have mild-to-moderate renal insufficiency and proteinuria less than 2 g/d, renal biopsy specimens are likely to show morphological findings consistent with the clinical diagnosis of HN. On the other hand, the diagnosis of HN in a white patient is unusual, and these findings suggest an alternative diagnosis.

**Imaging Studies:**

- An echocardiogram may be required to assess left ventricular size.
- Renal imaging with either an ultrasound or an intravenous pyelogram reveals that kidney size is usually symmetric and may be normal or modestly reduced.
- The renal calices and pelves are normal.
- Renal asymmetry or irregularities in the contour raise the possibility that hypertension could be secondary to renal artery stenosis or reflux nephropathy.

**Other Tests:**

- ECG typically shows left ventricular hypertrophy; however, this may not be evident on the tracings.

#### Procedures:

- A definitive diagnosis of HN cannot be made without a renal biopsy, especially in the white population. In the absence of a renal biopsy, the diagnosis of HN is one of exclusion.

**Histologic Findings:** Upon gross pathologic examination, the kidneys are shrunken and scarred. According to Tracy and Ishii (2000), the descriptive pathologic abnormalities of benign nephrosclerosis seen on renal biopsy specimens include glomeruli obsolescence, interstitial fibrosis, arterial intimal fibroplasia, arteriolar hyalinization in arterioles (most notably afferent), and small arteries (arcuate interlobular artery, see [Image 1](#)).

Myointimal hypertrophy of the interlobular arteries, hyaline degeneration, and sclerosis of afferent arterioles are the most characteristic findings of HN. Interlobular arteries often show reduplicated internal elastic lamina and medial hypertrophy. The arterial wall shows hyaline changes, apoptosis, eosinophilia, and distinctively periodic acid-Schiff–positive deposits (see [Image 2](#)). The arterioles are narrowed.

Early in the disease process, the glomeruli are normal. With time, ischemic changes become evident, including wrinkling of the glomerular tuft and thickening of the Bowman capsule (see [Image 3](#)). Occasionally, mild focal mesangial cell proliferation and matrix expansion occur. Eventually, chronic glomerular hyalinosis and obsolescence ensue with the development of secondary tubular atrophy and interstitial fibrosis (see [Image 4](#)). In contrast, the presence of enlarged glomeruli and the absence of collapse of the basement membrane suggest that the patient is most likely developing secondary nephrosclerosis superimposed on primary hypertensive disease.

With immunofluorescence, no specific pattern is noted, with the exception of an increased pre-precipitate immunoglobulin M deposits in the arterioles and mesangium. Fibrinoid necrosis and microinfarcts are features of malignant or accelerated hypertension, not nephrosclerosis. Of note, electron microscopy examination of renal biopsy specimens may help to distinguish primary FSGS from secondary FSGS; foot process effacement is widespread; in secondary FSGS, it is more localized.

As noted by Fogo et al (1997), none of the above lesions is pathognomonic. Consider the diagnosis of HN only when the constellation of these changes is present in the absence of other lesions of glomerular disease.

TREATMENT	Section 6 of 11 <a href="#">[Back]</a>
<a href="#">Author Information</a> <a href="#">Introduction</a> <a href="#">Clinical</a> <a href="#">Differentials</a> <a href="#">Workup</a> <a href="#">Treatment</a> <a href="#">Medication</a> <a href="#">Follow-up</a> <a href="#">Miscellaneous</a> <a href="#">Pictures</a> <a href="#">Bibliography</a>	

**Medical Care:** BP control is closely linked to the decline in cardiovascular and cerebrovascular rates over the last 3 decades. Recent epidemiologic studies underscore that even modest decline in renal function, usually identified by a serum creatinine level of greater than 1.4 mg/dL or estimated glomerular filtration rate of less than 60 mL/min, magnify long-term cardiovascular risk. One interpretation of these findings is that nephrosclerosis is part of generalized vascular disease elsewhere. With regard to antihypertensive therapy and ACE inhibitor administration, patients with cardiovascular disease and impaired renal function benefit proportionately more than those with normal kidney function. The National Kidney



Foundation has identified that a reduction in the cardiovascular risks associated with renal disease is a critical focus of the care of patients with renal disease.

Treatment of hypertension in patients with parenchymal renal disease is also effective in preserving renal function, particularly in proteinuric renal diseases such as diabetic nephropathy. Similarly, positive evidence suggests that antihypertensive treatment protects renal function in patients with malignant hypertension.

Remarkably, whether treating hypertension is effective to prevent ESRD attributed to HN is not clear. This is surprising because the percent of patients aware of their hypertension has increased from 68% to 84% over the last 20 years. At the same time, the percent of patients on medications increased from 68% to 73%. However, recent studies have shown that BP is adequately controlled (<140/90 mm Hg) in only 25-30% of patients taking antihypertensive medication.

Early data from large treatment surveys provide little information on the ability of antihypertensive treatment to prevent progressive renal deterioration in patients with essential hypertension. For example, Beevers and Lip (1996) analyzed the combined results of 9 major treatment trials of mild hypertension which included 21,826 patients. According to their analysis, the number of patients randomized to treatment who subsequently developed renal failure was the same (ie, 50) as those patients who were randomized to placebo treatment.

Similarly, among the 2125 cases of men with hypertension followed by Madhavan et al (1995), the evidence showed that controlling BP influenced renal function. Patients with hypertension who were treated for up to 5 years exhibited GFRs and renal plasma flow rates similar to those obtained in patients who were not treated. In the Hypertension Detection and Follow-up Program (HDFP), renal function was found to decline in some patients despite optimal antihypertensive treatment.

Zucchelli and Zuccalà (1998) followed the cases of 30 patients with essential hypertension for 20 years. In 15 of these patients, renal function was maintained, while the other 15 patients showed onset of renal impairment. Both groups were matched for age, sex, and treatment duration. At the end of the study, BP profiles indicated similar or better pressure control in patients with progressive renal disease compared with patients with normal renal function.

Similarly, Rostand et al (1989) retrospectively reviewed the records of 181 patients with hypertension. Patients with a primary renal disease diagnosed based on either suggestive medical history or biopsy findings, those with urinary protein excretion greater than or equal to 1.5 g/d or a serum creatinine level greater than or equal to 1.5 mg/dL were excluded from the analysis. Ninety-four patients were considered as having essential hypertension. Fourteen patients (15%) had an increase in their creatinine level greater than 0.4 mg/dL from baseline. However, renal function declined and was independent of the degree of BP control. In addition, Whelton and Klag (1989) reviewed 6 large antihypertensive treatment trials and reported that the total number of renal events was small, with no statistical difference between the treated groups and the placebo groups.

Toto et al (1995) reported on a long-term, prospective, randomized trial of 87 patients with the diagnosis of HN to determine whether strict versus conventional BP control was associated with a slower decline in renal function. In this trial, strict control of BP (ie, mean diastolic BP of 81 mm Hg  $\pm$  1.1) was not better than conventional BP control (ie, mean diastolic BP of 86.7 mm Hg  $\pm$  1.1) for preserving renal function; however, both groups experienced a slow decline in the GFR.



More recently, Hsu (2001) conducted a meta-analysis of 10 randomized controlled trials of antihypertensive drug therapy of more than 1 year's duration that reported renal dysfunction as outcome. Trials enrolling only those patients with known renal insufficiency or established renal parenchymal disease were excluded. Totals included 26,521 individuals, 114,000 person-year renal outcomes. This meta-analysis failed to demonstrate a difference between treated and untreated subjects regarding the development of ESRD. Notable limitations of this study were that the study did not address how stricter or longer-term control of BP would affect the incidence of renal dysfunction (2) was unable to evaluate the effects of newer classes of antihypertensive medications such as angiotensin inhibitors or angiotensin receptor blockers (ARBs).

Similarly, Ruilope et al (2001) reported on the renal function effect of intensive lowering of BP in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. Baseline serum creatinine values were available in 18,597 patients. Among them, 470 subjects had a serum creatinine value greater than 1.5 mg/dL. Their conclusion was that in contrast to patients with normal renal function, the frequency of major cardiovascular events did not differ in the 3 groups of patients with mild renal insufficiency randomized to different diastolic BP targets. In most patients, no significant change in serum creatinine values were noted at the end of the 3- to 9-year treatment period. However, a small group of patients (0.58% of the total study population) had deterioration of renal function (increase in serum creatinine >30% over baseline and final serum creatinine values >2 mg/dL) despite a satisfactory reduction in diastolic BP.

A criticism to the study is that systolic BP remained more than 10 mm Hg (mean) above the goal of less than 130 mm Hg, which has been recommended for patients with high serum creatinine levels. The difference in attained BP differed by only 4 mm Hg among the lowest and highest target groups (139.7-143.7 mm Hg). Whether tighter systolic BP control could have had an impact in this population with progressive renal impairment cannot be addressed with the available data. In any case, the group of hypertensive patients in whom renal function progressively deteriorated was small.

Studies of black patients with hypertension have not consistently shown a benefit of BP control on the progression of renal disease. Determining whether more intense BP control may slow renal disease progression in black patients is the objective of the AASK trial, the results of which have recently been published.

The study involved 1094 black people aged 18-70 years with GFRs from 20-65 mL/min/1.73 m<sup>2</sup> or other identified causes of renal insufficiency. Based on a 3 X 2 factorial design, participants were randomized equally to a usual mean arterial pressure goal of 102-107 mm Hg or to a lower goal of 92-97 mm Hg or lower and to treatment with 1 of 3 antihypertensive drugs (ie, beta-blocker, ACE inhibitor, or calcium channel blocker). The primary analysis was based on the rate of change in GFR (GFR slope). Secondary outcome included confirmed reduction in GFR by 50% or by 25 mL/min/1.73 m<sup>2</sup> from the mean of the 2 baseline GFRs, ESRD, or death.

After randomization, BP decreased from 152/96 mm Hg to 128/78 mm Hg in the lower BP goal group and from 149/95 mm Hg to 141/85 mm Hg in the usual BP goal group. A mean separation of approximately 10 mm Hg mean arterial pressure was maintained throughout most of the follow-up period. However, the mean GFR decline did not differ significantly between the lower and the usual BP groups during the follow-up period from baseline to 4 years. Similarly, the number of events (ie, rates/participant) for the main clinical composite outcome (ie, declining GFR events, ESRD, death) was no different between the BP groups. As such, results of the AASK trial do not support additional BP reduction as a means to prevent progression of HN.

These results are in agreement with previous findings in the MDRD study, which showed no eGFR decline in patients assigned to rigorous BP control (goal mean arterial pressure <92 mm Hg in participants <60 y or <98 mm Hg in participants >60 y) compared with the usual BP goal (ie, <113 mm Hg in participants <60 y or <113 mm Hg in participants >60 y). However, further analysis show protective effect of tight BP control in patients with proteinuria at baseline.

Finally, the Systolic Hypertension in the Elderly Program (SHEP) prospectively studied the relationship between baseline BP and an incident decline in kidney function among 2182 participants older than 60 years with serum creatinine values less than 2 mg/dL enrolled in the placebo arm of the study. A decline in kidney function was defined as an increase in serum creatinine values of greater than or equal to 0.4 mg/dL. Over the 5 years of follow-up, 226 subjects experienced an increase in serum creatinine greater than or equal to 0.4 mg/dL. A decline in kidney function was associated with systolic BP. The decline tended to be greater in persons with diabetes and in black persons. However, the report did not evaluate the relative contribution of patients in these 2 categories to the 226 persons with declining kidney function.

Taken together, in the universe of individuals with essential hypertension, a review of the evidence shows that (1) in patients with HN, the absolute risk of developing renal insufficiency that will lead to ESRD is low (as opposed to hypertension being a promoter of existing renal disease, which is an established fact) and (2) the progression of renal disease is not clearly related to hypertension because recent therapeutical trials have failed to demonstrate that intensive antihypertensive treatment slows the progression of renal diseases attributed to HN.

The following outlines the indications, effects, and adverse effects of the most commonly used antihypertensive medications.

## Diuretics

- Effects and indications
  - Induce natriuresis
  - Thiazide-induced vasodilation occurs
  - Reduce target organ morbidity and mortality in hypertension
  - Maximal BP-lowering effects achieved at low doses (12.5-25 mg/d)
  - Potentiate antihypertensive effects of all other blood pressure medications
  - Antihypertensive effect observed in all demographic groups
  - Thiazides superior to loop diuretics as antihypertensive agents.
- Adverse effects
  - Hypokalemia (dose dependent)
  - Hyperlipidemia (usually short-lived)

- Glucose intolerance (dose dependent)
- Hyperuricemia and gout (dose dependent)
- Thiazides ineffective when GFR is less than 30 mL/min
- Impotence
- Hypochloremic metabolic alkalosis (dose dependent)

### **ACE inhibitors**

- Effects and indications
  - Reduce proteinuria
  - Specific renal protective effect both in diabetic and nondiabetic renal impairment
  - Reduce morbidity and mortality rates in congestive heart failure
  - Monotherapy less effective in older patients (>50 y)
  - Larger doses required in black patients
  - Inhibit or blunt all adverse metabolic effects of thiazides
  - Dose reduction required in renal failure
  - Reduce left ventricular hypertrophy and thirst
- Adverse effects
  - Cough (approximately 10%)
  - Angioedema (rare)
  - Hyperkalemia (especially in renal tubular acidosis type IV)
  - GFR reduction in patients with impaired renal function
  - May precipitate acute renal failure in patients with renal artery stenosis
  - Interfere with breakdown of bradykinin
  - Contraindicated in pregnancy

### **Calcium channel blockers**

- **Effects and indications**
  - Effective as monotherapy in black patients and elderly patients
  - Potentiate ACE inhibitor effects
  - Renal protection not proven
  - Reduce morbidity and mortality rates in congestive heart failure
  - Indicated in patients with diastolic dysfunction
  - No change in dose with renal failure
- **Adverse effects**
  - Possible increase in cardiovascular mortality rate with short-acting dihydropyridines
  - Edema
  - Constipation (verapamil)
  - Profound bradycardia possible when verapamil and diltiazem used in combination with beta-blocker

## **Beta-blockers**

- **Effects and indications**
  - Precise mechanism of antihypertensive action unknown
  - Suppress renin secretion
  - Reduce morbidity and mortality rates after myocardial infarction
  - Possible dose adjustment of some beta-blockers required in renal failure
  - Monotherapy less effective in black patients
- **Adverse effects**
  - Bradyarrhythmia
  - Hypoglycemia unawareness
  - Bronchospasm
  - May precipitate heart failure

- Depression
- Lowers high-density lipoprotein levels and increases triglyceride levels

### **Vasodilators**

- Effects and indications
  - Arteriolar dilation by blocking arterial wall calcium uptake
  - Effective in severe hypertension (minoxidil is better than hydralazine)
  - Minoxidil most potent vasodilator available for oral use
  - No dose adjustment in renal failure
  - Best used in combination with a diuretic plus a beta-blocker
- Adverse effects
  - Reflex activation of sympathetic nervous system (headache, tachycardia)
  - Activation of renin-angiotensin system (sodium retention)
  - Loop diuretic possibly required to control edema
  - Hirsutism (minoxidil)
  - T-wave inversion in approximately 50% of patients on minoxidil

### **Angiotensin II receptor antagonists**

- Effects and indications
  - Reduce proteinuria
  - Indicated in patients intolerant of ACE inhibitors
  - Can be used in combination with an ACE inhibitor
  - Do not cause cough
  - Reduce left-ventricular hypertrophy and thirst similarly to ACE inhibitors
  - Do not interfere with breakdown of bradykinin
- Adverse effects

- Hyperkalemia
- May reduce GFR in patients with impaired renal function
- May precipitate acute renal failure in patient with renal artery stenosis
- Angioedema (rare)
- Data in black patients limited

### **Central-acting alpha-2 agonists**

- Effects and indications
  - Methyldopa drug of choice in pregnancy
  - Hypertensive emergency (clonidine)
  - Clonidine useful when patient has migraine in association with hypertension
- Adverse effects
  - Sedation
  - Orthostatic hypotension
  - Dry mouth, skin irritation (clonidine patch)
  - Rebound hypertension upon abrupt discontinuation
  - Possible Coombs-positive hemolytic anemia with methyldopa

### **Alpha-1 antagonists**

- Effects and indications
  - Improve insulin sensitivity
  - Improve urine flow in patients with benign prostatic hypertrophy
  - Reduce total cholesterol and triglyceride levels and increase high-density lipoprotein
- Adverse effects
  - Orthostatic hypotension
  - Caution when using in patients with autonomic neuropathy

<b>MEDICATION</b>	<b>Section 7 of 11</b> <a href="#">Back</a>
<a href="#">Author Information</a> <a href="#">Introduction</a> <a href="#">Clinical Differentials</a> <a href="#">Workup</a> <a href="#">Treatment</a> <a href="#">Medication</a> <a href="#">Follow-up</a> <a href="#">Miscellaneous</a> <a href="#">Pictures</a> <a href="#">Bibliography</a>	

## Antihypertensives

Several antihypertensive medications, including thiazide diuretics, beta-blockers, ACE inhibitors and calcium channel blockers, in principle, can be used as initial monotherapy in patients with hypertension. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure VII (JNC VII) has recommended the following for uncomplicated hypertension:

- Therapy begins with lifestyle modification.
- If the BP goal is not achieved, thiazide-type diuretics should be used as initial therapy for patients, either alone or in combination with one of the other classes (ie, ACE inhibitors, beta-blockers, calcium channel blockers) that have also been shown to reduce one or more hypertensive complications in randomized controlled outcome trials.
- Selection of one of these other agents as initial therapy is recommended when a diuretic is used or when a compelling indication requires the use of a specific drug.
- More than two thirds of hypertensive individuals do not achieve adequate control on one and require 2 or more antihypertensive agents selected from different drug classes.
- The initiation of therapy with more than one drug increases the likelihood of achieving the goal faster. The use of multidrug combinations often produces greater BP reduction at lower doses than the component agents, resulting in fewer adverse effects.
- Hypertension may exist in association with other conditions with compelling indications for particular treatment based on clinical trial data demonstrating benefits of such therapy or natural history of the associated condition. Compelling indications for specific therapy include high-risk conditions that can be direct sequelae of hypertension (eg, HF, ischemic heart disease, kidney disease, recurrent stroke) or commonly associated with hypertension (eg, diabetes, coronary disease risk). Therapeutic decisions in such individuals should be directed at both the compelling indication and lowering of BP.

### Low-dose thiazides

Low-dose thiazides are now recognized as achieving maximal effects on BP with minimal adverse effects. Results from multiple treatment trials show the benefits of low-dose diuretics and alpha-blockers in preventing stroke, coronary events, congestive heart failure, and all-cause mortality.

### ACE inhibitors

With the exception of ACE inhibitors in patients with diabetes, no data indicate the best way to treat patients with essential hypertension while preserving renal function. However, results obtained with the use of different antihypertensive treatment in patients with chronic renal failure and/or diabetes

animal and human studies) may be extrapolated to guide the treatment of patients with essential hypertension.

In animal models of chronic renal failure and diabetes, control of hypertension with the use of ACE inhibitors has been clearly demonstrated, and angiotensin II receptor antagonists can decrease proteinuria, reduce the severity of glomerulosclerosis and interstitial fibrosis, and slow the progression of renal disease.

Human studies show that ACE inhibitors are capable of slowing the progression of renal failure in various forms of nephropathy, except in patients with polycystic kidneys. Based on these and other results, ACE inhibitors have become the recommended initial therapy to treat hypertension in patients with chronic renal disease.

This recommendation is also supported by the results of the Heart Outcomes Prevention Evaluation (HOPE) trial. According to this study, an ACE inhibitor administered once daily reduces cardiovascular events in patients without heart failure but with at least one cardiovascular risk factor, not including diabetes. Similarly, the Microalbuminuria, Cardiovascular, and Renal Outcomes (MICRO-HOP) substudy of the HOPE trial randomized 3577 subjects with diabetes who had a prior cardiovascular event or at least one other cardiovascular risk factor and no clinical proteinuria to receive either ramipril (10 mg/d) or placebo. Treatment with ramipril resulted in a 24% risk reduction of overt nephropathy development after 4.5 years of follow-up care (independent of BP reduction).

The beneficial effect of ACE inhibitors is attributed, at least in part, to their ability to reduce or prevent proteinuria. This is particularly important for patients with diabetes because the development of microalbuminuria is associated with an increased prevalence of cardiovascular complications. Several studies have suggested that microalbuminuria is an early marker of renal damage in patients with hypertension, and patients with microalbuminuria experience a faster decline in renal function. Ravid et al (1994) reported a faster decline in creatinine clearance in patients who are hypertensive with microalbuminuria compared with patients who are hypertensive with normal albumin excretion (<30 mg/d vs 30-300 mg/d). Similar findings were observed by Bianchi et al (1999). In a few studies, ACE inhibitors, but not calcium channel blockers, reduced microalbuminuria in patients with essential hypertension. Other studies have also confirmed the ability of ACE inhibitors to reduce proteinuria in these patients.

Whether a reduction in microalbuminuria results in a decreased prevalence of ESRD in patients with hypertension remains to be determined. While combining an ACE inhibitor with a calcium channel blocker has been shown to reduce cardiovascular events in clinical trials of hypertension, the renoprotective effects are less uniformly demonstrated. Recent studies, including the Fosinopril and Amlodipine Cardiac Events Trial (FACET), the HOT study, and the Systolic Hypertension in Europe (Syst-Eur) trial, have reported conflicting results in terms of both cardiovascular and renal outcomes.

In the FACET, combination therapy with ACE inhibitors and calcium channel blockers resulted in significantly lower blood pressures compared with other groups. Moreover, combination therapy also showed the best results in reducing the mortality rate. To date, in patients with established renal failure (ie, creatinine >1.4 mg/dL), none of the dihydropyridine calcium channel blockers available in the United States has been shown to slow renal disease progression in the absence of an ACE inhibitor.

#### Alpha-blocker and ACE inhibitor combination

Alpha-adrenergic receptor blockers at low doses may be used as monotherapy in the treatment of hypertension.



hypertension. Alpha-adrenergic receptor blockers improve insulin sensitivity, improve urine flow, total cholesterol and triglyceride levels, and increase high-density lipoprotein levels.

Combinations of alpha-blockers and ACE inhibitors have additive effects for lowering BP only in patients with a baseline pulse rate that is greater than 84 beats per minute. In terms of slowing renal disease progression in patients with diabetes or impaired renal function, alpha-blockers are of no additional benefit. Some patients may require an additional arteriolar vasodilator to control BP. Finally, angiotensin II receptor blockers, alone or in combination with other antihypertensive medications, offer an alternative. Angiotensin II receptor blockers have a favorable adverse effect profile and appear to have the same beneficial effects of ACE inhibitors; however, no conclusive human data on renal disease progression are available for these agents.

Remember that only approximately 50% of patients with hypertension reach target BP control with antihypertensive monotherapy. Approximately 80-90% of patients require a second agent. The remaining 10-20% of the patients require a combination of 3 or more agents in order to reach target BP control.

**Drug Category: Diuretics** -- Induce natriuresis, reduce target organ morbidity and mortality in patients with hypertension, achieve maximal BP-lowering effects at low doses (12.5-25 mg/d), potentiate antihypertensive effects of other BP medications. Antihypertensive effect of these agents is observed in all demographic groups. Thiazides induce vasodilation and are superior to loop diuretics as antihypertensive agents.

<b>Drug Name</b>	Hydrochlorothiazide (Esidrix, HydroDIURIL) -- Inhibits reabsorption of sodium in distal tubules, causing increased excretion of sodium, water, potassium, and hydrogen ions.
<b>Adult Dose</b>	12.5-25 mg/d PO
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; anuria; renal decompensation
<b>Interactions</b>	May decrease effects of anticoagulants, antigout agents, and sulfonylureas; may increase toxicity of allopurinol, anesthetics, antineoplastics, calcium salts, loop diuretics, lithium, diazoxide, digitalis, amphotericin B, and nondepolarizing muscle relaxants
<b>Pregnancy</b>	C - Safety for use during pregnancy has not been established.
<b>Precautions</b>	Caution in renal or hepatic disease, gout, diabetes mellitus, and erythematosis

**Drug Category: Angiotensin-converting enzyme inhibitors** -- Reduce proteinuria, have renal protective effects in both diabetic and nondiabetic renal impairment, and reduce morbidity and mortality rates in congestive heart failure. Less effective as monotherapy if patient >50 y. Blacks require increased doses. Inhibit or blunt all adverse metabolic effects of thiazides, and reduce ventricular hypertrophy.

<b>Drug Name</b>	Fosinopril (Monopril) -- Prevents conversion of angiotensin I to angiotensin II, a potent
------------------	---

	vasoconstrictor, resulting in lower aldosterone secretion.
<b>Adult Dose</b>	10 mg/d PO initially; may increase to 20-40 mg/d PO
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; history of angioedema
<b>Interactions</b>	NSAIDs may reduce hypotensive effects; may increase digoxin, lithium, and allopurinol levels; rifampin decreases levels; probenecid may increase levels; hypotensive effects may be enhanced when administered concurrently with diuretics
<b>Pregnancy</b>	C - Safety for use during pregnancy has not been established.
<b>Precautions</b>	Category D in second and third trimester of pregnancy; caution in renal impairment, valvular stenosis, or severe CHF
<b>Drug Name</b>	Ramipril (Altace) -- Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion.
<b>Adult Dose</b>	10 mg PO qd
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; history of angioedema
<b>Interactions</b>	NSAIDs may reduce hypotensive effects; may increase digoxin, lithium, and allopurinol levels; rifampin decreases levels; probenecid may increase levels; hypotensive effects may be enhanced when administered concurrently with diuretics
<b>Pregnancy</b>	C - Safety for use during pregnancy has not been established.
<b>Precautions</b>	Category D in first trimester of pregnancy; caution in renal impairment, valvular stenosis, or severe CHF

**Drug Category: Angiotensin II receptor antagonists** -- Indicated in patients intolerant of ACE inhibitors because they do not interfere with the breakdown of bradykinin or cause cough. Red ventricular hypertrophy and thirst similarly to ACE inhibitors and reduce proteinuria.

<b>Drug Name</b>	Losartan (Cozaar) -- Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II. May induce a more complete inhibition of renin-angiotensin system than ACE inhibitors, does not affect response to bradykinin, and is less likely to be associated with cough and angioedema. For patients unable to tolerate ACE inhibitors. Angiotensin II receptor blockers reduce BP and proteinuria, protecting renal function and delaying onset of ESRD.
------------------	--

<b>Adult Dose</b>	50 mg PO qd initially; not to exceed 100 mg/d
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity
<b>Interactions</b>	Ketoconazole, sulfaphenazole, and phenobarbital may decrease effects; cimetidine may increase effects
<b>Pregnancy</b>	B - Usually safe but benefits must outweigh the risks.
<b>Precautions</b>	Caution in patients with unilateral or bilateral renal artery stenosis
<b>Drug Name</b>	Valsartan (Diovan) -- Prodrug that produces direct antagonism of angiotensin II receptors. Displaces angiotensin II from AT1 receptor and may lower BP by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. May induce more complete inhibition of renin-angiotensin system than ACE inhibitors, does not affect response to bradykinin, and is less likely to be associated with cough and angioedema. For patients unable to tolerate ACE inhibitors.
<b>Adult Dose</b>	80 mg/d PO qd; may increase to maximum 320 mg/d
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; severe hepatic insufficiency; biliary cirrhosis or obstruction; primary hyperaldosteronism; bilateral renal artery stenosis
<b>Interactions</b>	Ketoconazole, troleandomycin, sulfaphenazole, and phenobarbital may decrease effects; cimetidine and monoxidine may increase effects
<b>Pregnancy</b>	C - Safety for use during pregnancy has not been established.
<b>Precautions</b>	Caution in hyperkalemia, suspected bilateral renal artery stenosis, or solitary kidney with unilateral renal artery stenosis

**Drug Category:** *Calcium channel blockers* -- Effective as monotherapy in black patients & patients. Potentiate ACE inhibitor effects. Renal protection is not proven, but reduce morbidity mortality rates in congestive heart failure. Indicated in patients with diastolic dysfunction.

<b>Drug Name</b>	Verapamil (Calan, Covera, Verelan) -- During depolarization, inhibits calcium ion from entering slow channels or voltage-sensitive areas of vascular smooth muscle and myocardium.
<b>Adult Dose</b>	240-480 mg/d PO divided tid/qid
<b>Pediatric Dose</b>	Not established
	Documented hypersensitivity; severe CHF; sick sinus

<b>Contraindications</b>	syndrome or second- or third-degree AV block; hypotension (<90 mm Hg systolic)
<b>Interactions</b>	May increase carbamazepine, digoxin, and cyclosporine levels; coadministration with amiodarone can cause bradycardia and a decrease in cardiac output; may increase cardiac depression when administered concurrently with beta-blockers; cimetidine may increase levels; may increase theophylline levels
<b>Pregnancy</b>	B - Usually safe but benefits must outweigh the risks.
<b>Precautions</b>	Hepatocellular injury may occur; transient elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have occurred (elevations have been transient and may disappear with continued treatment); periodically monitor liver function; may cause constipation
<b>Drug Name</b>	Amlodipine (Norvasc) -- Relaxes coronary smooth muscle and produces coronary vasodilation, which, in turn, improves myocardial oxygen delivery. Benefits nonpregnant patients with systolic dysfunction, hypertension, or arrhythmias. Can be used during pregnancy if clinically indicated.
<b>Adult Dose</b>	2.5-5 mg PO qd; not to exceed 10 mg/d
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; severe CHF; sick sinus syndrome; second- or third-degree AV block; hypotension (<90 mm Hg systolic)
<b>Interactions</b>	May increase carbamazepine, digoxin, cyclosporine, and theophylline levels; coadministration with amiodarone may cause bradycardia and decrease in cardiac output; may increase cardiac depression when administered with beta-blockers
<b>Pregnancy</b>	C - Safety for use during pregnancy has not been established.
<b>Precautions</b>	Adjust dose in renal or hepatic impairment; may cause lower extremity edema; allergic hepatitis has occurred but is rare
<b>Drug Name</b>	Felodipine (Plendil) -- Relaxes coronary smooth muscle and produces coronary vasodilation, which, in turn, improves myocardial oxygen delivery.
<b>Adult Dose</b>	5 mg PO qd; not to exceed 20 mg/d
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; severe CHF; sick sinus syndrome; second- or third-degree AV block;

	hypotension (<90 mm Hg systolic)
<b>Interactions</b>	Bioavailability may be decreased with coadministration of barbiturates, carbamazepine, or hydantoins; effects may be increased with coadministration of erythromycin; may increase digoxin and cyclosporine levels; coadministration with amiodarone may cause bradycardia and decrease in cardiac output; may increase cardiac depression when administered with beta-blockers; with coadministration, theophylline levels may be slightly decreased
<b>Pregnancy</b>	C - Safety for use during pregnancy has not been established.
<b>Precautions</b>	Monitor BP closely during dosage adjustment; may cause greater hypotensive effect in elderly patients; adjust dose in renal or hepatic impairment; may cause lower extremity edema

**Drug Category: Beta-adrenergic blocking agents** -- Suppress renin secretion. Monotherapy effective in black patients. Reduce morbidity and mortality rates after myocardial infarction.

<b>Drug Name</b>	Labetalol (Normodyne, Trandate) -- Blocks beta1-, alpha-, and beta2-adrenergic receptor sites, decreasing BP.
<b>Adult Dose</b>	100 mg PO bid initially; not to exceed 2400 mg/d
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; cardiogenic shock; pulmonary edema; bradycardia; AV block; uncompensated congestive heart failure; reactive airway disease
<b>Interactions</b>	Decreases effect of diuretics and increases toxicity of methotrexate, lithium, and salicylates; may diminish reflex tachycardia resulting from nitroglycerin use without interfering with hypotensive effects; cimetidine may increase blood levels; glutethimide may decrease effects by inducing microsomal enzymes
<b>Pregnancy</b>	C - Safety for use during pregnancy has not been established.
<b>Precautions</b>	Caution in impaired hepatic function; discontinue therapy if signs of liver dysfunction are present; in elderly patients, a lower response rate and higher incidence of toxicity may be observed

**Drug Category: Vasodilators** -- Cause arteriolar dilation by blocking arterial wall calcium up Effective in severe hypertension (minoxidil more effective than hydralazine). Best if used in combination with a diuretic plus a beta-blocker.

	Minoxidil (Loniten) -- Most potent vasodilator
--	--

<b>Drug Name</b>	available for oral use. Relaxes arteriolar smooth muscle, causing vasodilation, which, in turn, may reduce BP.
<b>Adult Dose</b>	2.5-5 mg PO qd initially; increase gradually to maximum 100 mg/d
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; pheochromocytoma
<b>Interactions</b>	Concurrent use with guanethidine, diuretics, or hypotensive agents may result in additive hypotension
<b>Pregnancy</b>	C - Safety for use during pregnancy has not been established.
<b>Precautions</b>	May exacerbate angina pectoris; caution in pulmonary hypertension, CHF, coronary artery disease, and significant renal failure
<b>Drug Name</b>	Hydralazine (Apresoline) -- Decreases systemic resistance through direct vasodilation of arterioles.
<b>Adult Dose</b>	10 mg PO qid; not to exceed 300 mg/d
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; mitral valve rheumatic heart disease
<b>Interactions</b>	MAOIs and beta-blockers may increase toxicity; indomethacin may decrease pharmacologic effects
<b>Pregnancy</b>	B - Usually safe but benefits must outweigh the risks.
<b>Precautions</b>	Implicated in MI; caution in suspected coronary artery disease

**Drug Category: Alpha-adrenergic agonists** -- Improve hemodynamic status by increasing myocardial contractility and heart rate, resulting in increased cardiac output. Also increase peripheral resistance by causing vasoconstriction. Increased cardiac output and increased peripheral resistance lead to increased BP.

<b>Drug Name</b>	Methyldopa (Aldomet) -- DOC in pregnancy. Mechanism of action is likely due to drug's metabolism to alpha-methyl norepinephrine, which lowers arterial pressure by stimulating central inhibitory alpha-adrenergic receptors, false neurotransmission, or reducing plasma renin activity.
<b>Adult Dose</b>	250 mg PO bid/tid; increase q2d prn; not to exceed 3 g/d
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity; active hepatic disease; coadministration with MAOIs
	Coadministration with nonselective beta-blockers

<b>Interactions</b>	may cause paradoxical hypertension; may potentiate antipsychotic effects of haloperidol or produce psychosis; effects of lowering BP with methyldopa may be potentiated by levodopa; central effects of levodopa in Parkinson disease may be potentiated by methyldopa; may need reduced doses of anesthetics; coadministration with lithium may cause lithium toxicity; concurrent use with MAOIs leads to excessive sympathetic stimulation; coadministration with phenothiazines may cause serious BP elevation; may potentiate pressor effects of sympathomimetics; tolbutamide metabolism may be impaired, resulting in enhanced hypoglycemic effects; barbiturates and TCAs may reduce effects
<b>Pregnancy</b>	B - Usually safe but benefits must outweigh the risks.
<b>Precautions</b>	Perform periodic LFTs (particularly during first 6-12 wk); notify physician of unexplained prolonged tiredness, fever, or jaundice; urine may darken when exposed to air after voiding
<b>Drug Name</b>	Clonidine (Catapres) -- Stimulates alpha-2 adrenoreceptors in brain stem, activating an inhibitory neuron, which results in reduced sympathetic outflow. Decreases vasomotor tone and heart rates. Used in hypertensive emergency. Useful when patient has a migraine in association with hypertension.
<b>Adult Dose</b>	Initial: 0.1 mg PO bid Maintenance: 0.2-1.2 mg/d PO in 2-4 divided doses; not to exceed 2.4 mg/d
<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity
<b>Interactions</b>	TCAs inhibit hypotensive effects; coadministration with beta-blockers may potentiate bradycardia; TCAs may enhance hypertensive response associated with abrupt clonidine withdrawal; hypotensive effects enhanced by narcotic analgesics
<b>Pregnancy</b>	C - Safety for use during pregnancy has not been established.
<b>Precautions</b>	Caution in cerebrovascular disease, coronary insufficiency, sinus node dysfunction, and renal impairment
<b>Drug Name</b>	Doxazosin (Cardura) -- Inhibits postsynaptic alpha-adrenergic receptors, resulting in vasodilation of veins and arterioles and decrease in total peripheral resistance and BP.
<b>Adult Dose</b>	1 mg PO hs; not to exceed 16 mg/d



<b>Pediatric Dose</b>	Not established
<b>Contraindications</b>	Documented hypersensitivity
<b>Interactions</b>	Effects decrease with coadministration of NSAIDs; effects increase with coadministration of diuretics and antihypertensive medications
<b>Pregnancy</b>	B - Usually safe but benefits must outweigh the risks.
<b>Precautions</b>	Caution in renal impairment; may cause marked hypotension following first dose; may worsen CHF
<b>FOLLOW-UP</b>	<b>Section 8 of 11</b> <a href="#">Back</a>
<a href="#">Author Information</a> <a href="#">Introduction</a> <a href="#">Clinical Differentials</a> <a href="#">Workup</a> <a href="#">Treatment</a> <a href="#">Medication</a> <a href="#">Follow-up</a> <a href="#">Miscellaneous</a> <a href="#">Pictures</a> <a href="#">Bibliography</a>	

### Deterrence/Prevention:

- Hypertension complicating primary renal disease
  - Systemic hypertension clearly induces or accelerates the progression of renal disease in experimental models. In these models, BP control reduces proteinuria and prevents deterioration of renal function.
  - Similarly, in a variety of primary human renal diseases, BP strongly predicts a faster decline in the GFR.
  - As demonstrated by the MDRD study, even small differences in mean arterial pressure between the usual BP control group and the low-BP group had significant effects on renal disease progression.

### Complications:

- Traditionally, nephrosclerosis was considered the consequence of long-term hypertensive disease. This premise is based on observations of rapidly progressive renal failure developing in some cases with malignant hypertension. Such individuals demonstrate arterial and necrotizing lesions of the kidneys, which may be reversed with effective BP control. However, less severe hypertension is suggested to cause renal failure only rarely, and progressive renal impairment is usually secondary to undiagnosed primary renal disease.
  - Madhavan et al (1995) followed the cases of 2125 men with mild-to-moderate hypertension for 5 years and found no change in serum creatinine values. Similarly, Tomson et al (1995) followed the cases of 176 patients with essential hypertension for more than 14 years and found no change in serum creatinine values, with none of the patients developing renal failure.
  - In the Baltimore Longitudinal Study on Aging, the cases of 446 patients who are predominantly white and of middle or upper socioeconomic status were followed over a 10-year period. In this study, patients with hypertension had a decline in their GFRs at a faster rate than normotensive subjects (0.92 mL/min/1.73 m<sup>2</sup>/y vs 0.75 mL/min/1.73 m<sup>2</sup>/y). Although this study showed that patients with hypertension lost renal function at a faster rate with aging,



normotensive subjects, the rate of decline in renal function was small and unlikely to lead to ESRD. More importantly, this study failed to determine whether the decline in renal function was secondary to essential hypertension or was the result of undiagnosed primary renal disease.

- In a review of the British Health System data on hypertension and nephrosclerosis, Beevers and Lip (1996) noted that baseline proteinuria or renal impairment was evident at entry in all patients who later developed significant renal failure. More importantly, these authors did not find any reported cases of patients who went on to develop renal failure who had essential hypertension with reference range serum creatinine levels and no evident proteinuria.
- On the other hand, Rosansky et al (1990) reported on the cases of 56 patients with hypertension, all of whom had creatinine levels within the reference range and no proteinuria at the beginning of the observation, and compared them with 59 normotensive control patients. At an average of 9.8 years, the rate of decline in renal function was significantly higher in the patients with hypertension than in the control patients; however, the authors stated that the diagnostic criteria for hypertensive renal disease often was not fulfilled.
- Finally, Klag et al (1996), in the largest prospective trial to date, primarily intended to study the cardiovascular risk associated with hypertension. The MRFIT analyzed the cases of 332,544 men (90.4% white) whose cases were followed for an average of 16 years. The study showed a strong graded relationship between BP (the relative risk of developing ESRD varied from 2.8-12.4 as diastolic BP increased from 90-120 mm Hg) and the subsequent development of ESRD; however, most patients with progressive renal failure had a cause other than essential hypertension. Furthermore, this tendency to develop an elevated serum creatinine level appears to have been largely a feature of the black population. No changes in the reciprocal creatinine slope were observed in white patients; however, significant declines in renal function were observed in the black patients.
- In 1997, the same group of authors (Brancati et al) reevaluated data from the MRFIT time aiming to determine the relative risk of ESRD related to diabetes. Their conclusion was that diabetes mellitus is a strong independent risk factor for ESRD, even for ESRD due to causes other than diabetes (by year 15 of follow-up, the cumulative ESRD incidence had risen to 2.97% in diabetic men). However, if baseline diabetes mellitus is removed, the risk attributable to hypertension to cause ESRD is almost negligible (0.19%; this number may be actually lower because 8.4% of cases of ESRD in men without diabetes at baseline were classified as diabetic ESRD). Noted that a greater proportion of diabetic men, compared to nondiabetic men, were black (12.6% vs 6%). Diabetic men were also approximately older on average and had higher blood systolic and diastolic pressures than their non-diabetic counterparts.
- The significant decline in renal function observed in black patients confirmed similar observations by the HDFP. In this study, of the 8000 patients with normal renal function at outset, only 110 had a significant increase in serum creatinine values over time; this was largely confined to black people. In further agreement with Beevers and Lip's observations outlined above, the patients with the highest serum creatinine levels at presentation had the largest reduction in renal function, implying that subclinical renal damage was present from the beginning. Neither the HDFP nor the MRFIT provide

information regarding whether participants had proteinuria at presentation. In addition, these studies do not rule out the possibility that patients who progressed had some form of glomerulonephritis because participants did not undergo renal biopsies.

- Zucchelli and Zuccalà (1993) reviewed the cases of 136 patients who were originally diagnosed with benign nephrosclerosis but actually represented a heterogeneous group. In these patients, a thorough diagnostic workup, including renal biopsy, reconfirmed nephrosclerosis as the correct diagnosis in many of the patients (44%), although 50 patients were reclassified as having cholesterol microembolism (29%) or renovascular hypertension (26.5%). Schlessinger et al (1994) made a similar observation when they reviewed the cases of 233 patients undergoing evaluation as candidates for renal transplantation. Schlessinger et al found that their referring physicians diagnosed 44 patients with ESRD secondary to HN. After extensive review of the patients' medical history, laboratory evaluations, and available renal biopsy results, the authors concluded that the 43 patients met the clinical criteria for HN.
- A further complication is that many patients already have advanced renal failure at presentation. Qualheim et al (1991) reported that at the time patients with presumed nephrosclerosis presented to a nephrologist, their serum creatinine values were close to 7 mg/dL in white patients and 9.4 mg/dL in black patients. Diagnosing HN in these patients can be difficult because of the inability to identify the initial process. However, in black patients, a closer correlation between clinical and histological diagnoses of HN has been reported.
- In the AASK, 88 black patients who did not have diabetes or hypertension but who had moderate renal insufficiency and absent marked proteinuria were asked to undergo renal biopsy. Forty-six patients agreed, and 39 biopsies were performed. The mean arterial pressure of these patients was  $109 \text{ mm Hg} \pm 15 \text{ mm Hg}$ , and their mean GFR was  $25 \pm 13 \text{ mL/min}$ . In nearly 85% of the cases, renal biopsy results showed arteriosclerosis, arteriolosclerosis, interstitial fibrosis, thickening of the basement membrane, and glomerulosclerosis consistent with the clinical diagnosis of HN. The conclusion of the study was that in black people who do not have diabetes or hypertension but who have decreased renal function and mild proteinuria, renal biopsy findings are likely to be consistent with the clinical diagnosis of HN.
- Considering that approximately 60 million individuals with hypertension live in the United States, only 19,000 (1 in 2200) develop ESRD, factors other than hypertension have been postulated to participate in the progression of renal failure. Hyperlipidemia, insulin resistance, hyperuricemia, immune-mediated factors, and other unrecognized mechanisms may play a role. In this context, HN is possibly a disease primarily of the small renal vessels, with glomerular changes being secondary to the vascular process. Autopsy studies of patients with mild, moderate, and severe vascular disease found an independent correlation between glomerulosclerosis and atherosclerosis. Appel (1999) found that 52% of white patients diagnosed with HN had at least one focus of atherosclerosis at baseline.
- Clinical and experimental evidence indicates that histologic lesions indistinguishable from those seen in conditions associated with BP values within the reference range, such as in patients with the metabolic syndrome. Nephrosclerosis is also observed spontaneously with aging, especially in patients older than 60 years. Diabetes mellitus markedly increases the presence and severity of nephrosclerosis in all age groups; as such, nephrosclerosis appears to be the common final pathway of

processes that cause injury to small intrarenal vessels.

### Prognosis:

- With regard to the target BP, the Working Group Report on Hypertension and Diabetes recommended a BP goal of less than 130/80 mm Hg in order to preserve renal function and cardiovascular events in patients with hypertension and diabetes. Lower BPs are recommended in patients with proteinuria greater than 1 g/d and renal insufficiency, regardless of etiology. The optimal BP goal to slow the progression of renal failure in patients with HN currently is uncertain.
- HN remains a poorly defined entity. Researchers continue to search for a clear definition, pathophysiologic mechanism, and optimal treatment for patients with this condition. As stated by Meyrier (1996), HN may conceivably be a primary microvascular nephropathy.
- Uncontrolled hypertension can accelerate the decline of renal function in patients with prerenal disease; however, whether mild-to-moderate essential hypertension can cause ESRD in people is uncertain. The available data do not support the hypothesis that high BP is the determining factor for ESRD in these patients.
- Medical treatment is indicated in any patient with BP higher than 140/90 mm Hg. In these patients, antihypertensive treatment has proven to reduce the risk of stroke and cardiovascular mortality. Evidence for the beneficial effect of hypertension treatment on patients with HN is lacking. Many questions regarding the ability of these drugs to protect renal function in the long term remain unanswered.

<b>MISCELLANEOUS</b>	<b>Section 9 of 11</b> <a href="#">[Back]</a>
<a href="#">Author Information</a> <a href="#">Introduction</a> <a href="#">Clinical</a> <a href="#">Differentials</a> <a href="#">Workup</a> <a href="#">Treatment</a> <a href="#">Medication</a> <a href="#">Follow-up</a> <a href="#">Miscellaneous</a> <a href="#">Pictures</a> <a href="#">Bibliography</a>	

### Medical/Legal Pitfalls:


- Failure to diagnose a treatable cause of hypertension and progressive renal failure by labeling a patient as having HN without excluding other likely causes

### Special Concerns:

- Oral contraceptives (eg, birth control pill) are the most common cause of drug-induced hypertension.

<b>PICTURES</b>	<b>Section 10 of 11</b> <a href="#">[Back]</a>
<a href="#">Author Information</a> <a href="#">Introduction</a> <a href="#">Clinical</a> <a href="#">Differentials</a> <a href="#">Workup</a> <a href="#">Treatment</a> <a href="#">Medication</a> <a href="#">Follow-up</a> <a href="#">Miscellaneous</a> <a href="#">Pictures</a> <a href="#">Bibliography</a>	

**Caption:** Picture 1. Nephrosclerosis. The glomerular tuft is shrunken, with wrinkling of the capillary walls (asterisk), global glomerular sclerosis (arrow), and complete obliteration of the capillary loops and glomerular ischemia (periodic acid-Schiff stain at 250X magnification).


[View Full Size Image](#)

[eMedicine Zoom View  
\(Interactive!\)](#)

**Picture Type:** Photo


**Caption:** Picture 2. Nephrosclerosis. Glomerulus with wrinkling of glomerular basement membranes accompanied by reduction of capillary lumen diameter (silver stain at 400X magnification).


[View Full Size Image](#)

[eMedicine Zoom View  
\(Interactive!\)](#)

**Picture Type:** Photo


**Caption:** Picture 3. Nephrosclerosis. Hyaline arteriosclerosis with hyaline deposits (arrows) (trichrome stain at 250X magnification).


[View Full Size Image](#)

[eMedicine Zoom View  
\(Interactive!\)](#)

**Picture Type:** Photo

**Caption:** Picture 4. Nephrosclerosis. Fibrointimal proliferation of the arcuate artery (periodic acid-Schiff stain at 150X magnification).


[View Full Size Image](#)

[eMedicine Zoom View  
\(Interactive!\)](#)

**Picture Type:** Photo

## BIBLIOGRAPHY

Section 11 of 11 [Back](#)

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

- Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inh

- arresting progressive renal disease associated with systemic hypertension in the rat. *J C* 1986 Jun; 77(6): 1993-2000[[Medline](#)].
- Anderson S, Rennke HG, Zatz R: Glomerular adaptations with normal aging and with losartan converting enzyme inhibition in rats. *Am J Physiol* 1994 Jul; 267(1 Pt 2): F35-43[[Medline](#)]
  - Appel RG, Bleyer AJ, Reavis S, Hansen KJ: Renovascular disease in older patients beginning renal replacement therapy. *Kidney Int* 1995 Jul; 48(1): 171-6[[Medline](#)].
  - Bakris GL, Williams M, Dworkin L, et al: Preserving renal function in adults with hypertensive diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. *Am J Kidney Dis* 2000 Sep; 36(3): 646-61[[Medline](#)].
  - Beevers DG, Lip GY: Does non-malignant essential hypertension cause renal damage? A clinician's view. *J Hum Hypertens* 1996 Oct; 10(10): 695-9[[Medline](#)].
  - Belz GG, Breithaupt K, Erb K, et al: Influence of the angiotensin converting enzyme inhibitor lisinopril, the beta-blocker propranolol and their combination on haemodynamics in hypertensive rats. *Hypertens* 1989 Oct; 7(10): 817-24[[Medline](#)].
  - Bianchi S, Bigazzi R, Baldari G, Campese VM: Microalbuminuria in patients with essential hypertension. Effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker. *Am J Hypertens* 1991 Apr; 4(4 Pt 1): 291-6[[Medline](#)].
  - Bianchi S, Bigazzi R, Campese VM: Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. *Am J Kidney Dis* 1999 Dec; 34(6): 973-9[[Medline](#)].
  - Bidani AK, Schwartz MM, Lewis EJ: Renal autoregulation and vulnerability to hypertension in the remnant kidney. *Am J Physiol* 1987 Jun; 252(6 Pt 2): F1003-10[[Medline](#)].
  - Blantz RC, Gabbaï F, Gushwa LC, Wilson CB: The influence of concomitant experimental diabetes mellitus on hypertension and glomerulonephritis. *Kidney Int* 1987 Nov; 32(5): 652-63[[Medline](#)].
  - Bleyer AJ, Appel RG: Risk factors associated with hypertensive nephrosclerosis. *Nephrol* (3): 193-8[[Medline](#)].
  - Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH: The serum angiotensinogen concentration and polymorphisms of the angiotensinogen gene in white and black children. *J Clin Invest* 1995 Mar; 95: 948-53[[Medline](#)].
  - Brancati FL, Whelton PK, Randall BL, et al: Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. *Am J Epidemiol* 1997 Dec 17; 146(12): 2069-74[[Medline](#)].
  - Brenner BM, Chertow GM: Congenital oligonephropathy and the etiology of adult hypertensive progressive renal injury. *Am J Kidney Dis* 1994 Feb; 23(2): 171-5[[Medline](#)].
  - Brown DM, Provoost AP, Daly MJ, et al: Renal disease susceptibility and hypertension are independently inherited in the fawn-hooded rat. *Nat Genet* 1996 Jan; 12(1): 44-51[[Medline](#)].
  - Caetano EP, Zatz R, Praxedes JN: The clinical diagnosis of hypertensive nephrosclerosis: how reliable is it? *Nephrol Dial Transplant* 1999 Feb; 14(2): 288-90[[Medline](#)].
  - Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. *Lancet* 1990 Apr 7; 335(8693): 827-38[[Medline](#)].
  - D'Amico G: Comparability of the different registries on renal replacement therapy. *Am J Kidney Dis* 1995 Jan; 25(1): 113-8[[Medline](#)].
  - De Venuto G, Andreotti C, Mattarei M, Pegoretti G: Long-term captopril therapy at low dose reduces albumin excretion in patients with essential hypertension and no sign of renal impairment. *J Hypertens Suppl* 1985 Nov; 3(2): S143-5[[Medline](#)].
  - Duru K, Farrow S, Wang JM, et al: Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African-Americans with hypertension. *Am J Hypertens* 1994 Aug; 7(8): 759-62[[Medline](#)].
  - Dworkin LD, Grosser M, Feiner HD, et al: Renal vascular effects of antihypertensive therapy in uninephrectomized SHR. *Kidney Int* 1989 Mar; 35(3): 790-8[[Medline](#)].

- Feld LG, Van Liew JB, Brentjens JR, Boylan JW: Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment. *Kidney Int* 1981 Nov; 14[[Medline](#)].
- Ferguson R, Grim CE, Oppenorth TJ: A familial risk of chronic renal failure among blacks on dialysis? *J Clin Epidemiol* 1988; 41(12): 1189-96[[Medline](#)].
- Fisher ER: Ultrastructural changes in renal arterioles and juxtaglomerular cells in hypertension. *Heart J* 1971 Jan; 81(1): 125-35[[Medline](#)].
- Fogo A, Breyer JA, Smith MC, et al: Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Pilot Study Investigators. *Kidney Int* 1997 Jan; 51(1): 244-52[[Medline](#)].
- Fox CS, Larson MG, Leip EP, et al: Predictors of new-onset kidney disease in a community-based population. *JAMA* 2004 Feb 18; 291(7): 844-50[[Medline](#)].
- Freedman BI, Spray BJ, Tuttle AB, Buckalew VM Jr: The familial risk of end-stage renal disease in African Americans. *Am J Kidney Dis* 1993 Apr; 21(4): 387-93[[Medline](#)].
- Freedman BI, Soucie JM, McClellan WM: Family history of end-stage renal disease among dialysis patients. *J Am Soc Nephrol* 1997 Dec; 8(12): 1942-5[[Medline](#)].
- Freedman BI, Iskandar SS, Appel RG: The link between hypertension and nephrosclerosis. *Kidney Dis* 1995 Feb; 25(2): 207-21[[Medline](#)].
- Freedman BI, Iskander SS, Buckalew VM Jr, et al: Renal biopsy findings in presumed hypertensive nephrosclerosis. *Am J Nephrol* 1994; 14(2): 90-4[[Medline](#)].
- Goldring W, Chasis H, Ranges HA: Effective renal blood flow in subjects with essential hypertension. *J Clin Invest* 1941; 20: 637-53.
- Greenberg A, Bastacky SI, Iqbal A, et al: Focal segmental glomerulosclerosis associated with a nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations. *Am J Kidney Dis* 1997 Mar; 29(3): 334-44[[Medline](#)].
- Hansen KJ, Edwards MS, Craven TE, et al: Prevalence of renovascular disease in the elderly: a population-based study. *J Vasc Surg* 2002 Sep; 36(3): 443-51[[Medline](#)].
- Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet* 1998 Jun 13; 351(9118): 1755-62[[Medline](#)].
- Harvey JM, Howie AJ, Lee SJ: Renal biopsy findings in hypertensive patients with proteinuria. *Lancet* 1992 Dec 12; 340(8833): 1435-6[[Medline](#)].
- Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular morbidity and microvascular outcomes in people with diabetes mellitus: results of the HOPE study MICRO-HOPE substudy. *Lancet* 2000 Jan 22; 355(9200): 253-9[[Medline](#)].
- Hebert LA, Kusek JW, Greene T, et al: Effects of blood pressure control on progressive chronic kidney disease in blacks and whites. Modification of Diet in Renal Disease Study Group. *Hypertension* 1997 Sep; 30(3 Pt 1): 428-35[[Medline](#)].
- Heptinstall RH: Hypertension II. Essential hypertension. In: Heptinstall RH, ed. *Pathology of the Kidney*. Boston, Mass: Little Brown; 1983: 181-246.
- Himmelmann A, Hansson L, Hansson BG, et al: ACE inhibition preserves renal function in the presence of beta-blockade in the treatment of essential hypertension. *Blood Press* 1995 Mar; 4(2): 85-9[[Medline](#)].
- Hsu CY: Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. *Curr Opin Nephrol Hypertens* 2002 May; 11(3): 267-72[[Medline](#)].
- Hunley TE, Julian BA, Phillips JA 3rd, et al: Angiotensin converting enzyme gene polymorphism, a potential silencer motif and impact on progression in IgA nephropathy. *Kidney Int* 1996 Feb; 50(2): 571-7[[Medline](#)].
- Hunsicker LG, Adler S, Caggiula A, et al: Predictors of the progression of renal disease in type 2 diabetes mellitus. Modification of Diet in Renal Disease Study. *Kidney Int* 1997 Jun; 51(6): 1908-19[[Medline](#)].



- Innes A, Johnston PA, Morgan AG, et al: Clinical features of benign hypertensive nephropathy at time of renal biopsy. *Q J Med* 1993 Apr; 86(4): 271-5[[Medline](#)].
- Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure [published erratum appears in *Arch Intern Med* 1998 Mar 23; 158(6): *Intern Med* 1997 Nov 24; 157(21): 2413-46[[Medline](#)].
- Kasiske BL: Relationship between vascular disease and age-associated changes in the kidney. *Kidney Int* 1987 May; 31(5): 1153-9[[Medline](#)].
- Keith TA 3d: Renovascular hypertension in black patients. *Hypertension* 1982 May-Jun; 4: 43[[Medline](#)].
- Kincaid-Smith P: Renal pathology in hypertension and the effects of treatment. *Br J Clin Pharmacol* 1982 Jan; 13(1): 107-15[[Medline](#)].
- Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in the United States. *Engl J Med* 1996 Jan 4; 334(1): 13-8[[Medline](#)].
- Klahr S, Levey AS, Beck GJ, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Group. *N Engl J Med* 1994 Mar 31; 330(13): 877-84[[Medline](#)].
- Lazarus JM, Bourgoignie JJ, Buckalew VM, et al: Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. *Hypertension* 1997 Feb; 29(2): 641-50[[Medline](#)].
- Levy SB, Talner LB, Coel MN, et al: Renal vasculature in essential hypertension: racial differences. *Ann Intern Med* 1978 Jan; 88(1): 12-6[[Medline](#)].
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med* 1993 Nov 11; 329(20): 1456-62[[Medline](#)].
- Li L: End-stage renal disease in China. *Kidney Int* 1996 Jan; 49(1): 287-301[[Medline](#)].
- Lindeman RD, Tobin JD, Shock NW: Association between blood pressure and the rate of decline of renal function with age. *Kidney Int* 1984 Dec; 26(6): 861-8[[Medline](#)].
- Locatelli F, Marcelli D, Comelli M, et al: Proteinuria and blood pressure as causal components in the progression to end-stage renal failure. Northern Italian Cooperative Study Group. *Nephrol Dial Transplant* 1996 Mar; 11(3): 461-7[[Medline](#)].
- Luke RG: Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension: an important cause of end-stage renal disease. *Nephrol Dial Transplant* 1999 Oct; 14(10): 1000-1001[[Medline](#)].
- Luke RG, Curtis JJ: Nephrosclerosis. In: Schrier RW, Gottschalk CW, eds. *Disease of the Kidney*. Boston, Mass: Little Brown; 1993: 1433-50.
- Madhavan S, Stockwell D, Cohen H, Alderman MH: Renal function during antihypertensive treatment. *Lancet* 1995 Mar 25; 345(8952): 749-51[[Medline](#)].
- Magee JH, Unger AM, Richardson DW: Changes in renal function associated with drug therapy of human hypertension. *Am J Med* 1964 May; 36: 795-804[[Medline](#)].
- Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting-enzyme inhibitor lisinopril on the progression of chronic renal insufficiency. The Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. *N Engl J Med* 1996 Apr 11; 334(15): 1045-52[[Medline](#)].
- McClellan W, Tuttle E, Issa A: Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. *Kidney Dis* 1988 Oct; 12(4): 285-90[[Medline](#)].
- Meyrier A, Hill GS, Simon P: Ischemic renal diseases: new insights into old entities. *Kidney Int* 1997 Jul; 52(1): 2-13[[Medline](#)].
- Meyrier A, Simon P: Nephroangiosclerosis and hypertension: things are not as simple as they seem. *Nephrol Dial Transplant* 1997 Oct; 12(10): 1000-1001[[Medline](#)].

think. *Nephrol Dial Transplant* 1996 Nov; 11(11): 2116-20[[Medline](#)].

- Meyrier A: Renal vascular lesions in the elderly: nephrosclerosis or atheromatous renal c  
*Nephrol Dial Transplant* 1996; 11 Suppl 9: 45-52[[Medline](#)].
- Mujais SK, Emmanouel DS, Kasinath BS, Spargo BH: Marked proteinuria in hypertensive nephrosclerosis. *Am J Nephrol* 1985; 5(3): 190-5[[Medline](#)].
- Narvarte J, Privé M, Saba SR, Ramirez G: Proteinuria in hypertension. *Am J Kidney Dis* 10(6): 408-16[[Medline](#)].
- Neugarten J, Alfino P, Langs C, et al: Nephrotoxic serum nephritis with hypertension: per pressure and permselectivity. *Kidney Int* 1988 Jan; 33(1): 53-7[[Medline](#)].
- Ofstad J, Iversen BM: The interlobular artery: its possible role in preventing and mediatin disorders. *Nephrol Dial Transplant* 1988; 3(2): 123-9[[Medline](#)].
- Olin JW: Atherosclerotic renal artery disease. *Cardiol Clin* 2002 Nov; 20(4): 547-62, vi[[M](#)
- Ono H, Ono Y: Nephrosclerosis and hypertension. *Med Clin North Am* 1997 Nov; 81(6): [[Medline](#)].
- Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the prog renal disease. The Modification of Diet in Renal Disease Study. *Ann Intern Med* 1995 Nc (10): 754-62[[Medline](#)].
- Pitt B, Segal R, Martinez FA, et al: Randomised trial of losartan versus captopril in patier with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 1997 Mar (9054): 747-52[[Medline](#)].
- Psaty BM, Smith NL, Siscovick DS, et al: Health outcomes associated with antihypertens therapies used as first-line agents. A systematic review and meta-analysis. *JAMA* 1997 I (9): 739-45[[Medline](#)].
- Puig JG, Mateos FA, Ramos TH, et al: Albumin excretion rate and metabolic modification patients with essential hypertension. Effects of two angiotensin converting enzyme inhibi *Hypertens* 1994 Jan; 7(1): 46-51[[Medline](#)].
- Qualheim RE, Rostand SG, Kirk KA, et al: Changing patterns of end-stage renal disease hypertension. *Am J Kidney Dis* 1991 Sep; 18(3): 336-43[[Medline](#)].
- Raij L, Azar S, Keane WF: Role of hypertension in progressive glomerular immune injury *Hypertension* 1985 May-Jun; 7(3 Pt 1): 398-404[[Medline](#)].
- Ravid M, Savin H, Jutrin I, et al: Long-term stabilizing effect of angiotensin-converting en inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patient *Intern Med* 1993 Apr 15; 118(8): 577-81[[Medline](#)].
- Reams GP, Lau A, Knaus V, Bauer JH: Short- and long-term effects of spirapril on renal hemodynamics in patients with essential hypertension. *J Clin Pharmacol* 1993 Apr; 33(4), [[Medline](#)].
- Reubi FC, Weidmann P, Hodler J, Cottier PT: Changes in renal function in essential hyp *Am J Med* 1978 Apr; 64(4): 556-63[[Medline](#)].
- Rimmer JM, Gennari FJ: Atherosclerotic renovascular disease and progressive renal fail *Intern Med* 1993 May 1; 118(9): 712-9[[Medline](#)].
- Rosansky SJ, Hoover DR, King L, Gibson J: The association of blood pressure levels an in renal function in hypertensive and nonhypertensive subjects. *Arch Intern Med* 1990 Oc 2073-6[[Medline](#)].
- Rostand SG, Brown G, Kirk KA, et al: Renal insufficiency in treated essential hypertensic *J Med* 1989 Mar 16; 320(11): 684-8[[Medline](#)].
- Ruggenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channe angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondial nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). *J Am Soc* 1998 Nov; 9(11): 2096-101[[Medline](#)].
- Ruilope LM, Alcázar JM, Hernández E, et al: Long-term influences of antihypertensive th



- microalbuminuria in essential hypertension. *Kidney Int Suppl* 1994 Feb; 45: S171-3[[Medline](#)].
- Ruilope LM, Campo C, Rodriguez-Artalejo F, et al: Blood pressure and renal function: the implications. *J Hypertens* 1996 Nov; 14(11): 1259-63[[Medline](#)].
  - Ruilope LM, Salvetti A, Jamerson K, et al: Renal function and intensive lowering of blood in hypertensive participants of the hypertension optimal treatment (HOT) study. *J Am Soc Hypertens* 2001 Feb; 12(2): 218-25[[Medline](#)].
  - Schelling JR, Zarif L, Sehgal A, et al: Genetic susceptibility to end-stage renal disease. *Clin Nephrol Hypertens* 1999 Jul; 8(4): 465-72[[Medline](#)].
  - Schlessinger SD, Tankersley MR, Curtis JJ: Clinical documentation of end-stage renal disease due to hypertension. *Am J Kidney Dis* 1994 May; 23(5): 655-60[[Medline](#)].
  - Sheinfeld GR, Bakris GL: Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. *Am J Hypertens* 1999 Aug; 12(8 Pt 2): 8S-13[[Medline](#)].
  - Shulman NB, Ford CE, Hall WD, et al: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. *Hypertension* 1991 May; 13(5 Suppl): I80-93[[Medline](#)].
  - Sterzel RB, Luft FC, Gao Y, et al: Renal disease and the development of hypertension in sensitive Dahl rats. *Kidney Int* 1988 Jun; 33(6): 1119-29[[Medline](#)].
  - Tatti P, Pahor M, Byington RP, et al: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998 Apr; 21(4): 597-603[[Medline](#)].
  - Teo KK: Angiotensin-converting enzyme genotypes and disease. *BMJ* 1995 Sep 23; 311(6984): 763-4[[Medline](#)].
  - Textor SC: Managing renal arterial disease and hypertension. *Curr Opin Cardiol* 2003 Jun; 18(3): 260-7[[Medline](#)].
  - Tomson CR, Petersen K, Heagerty AM: Does treated essential hypertension result in renal impairment? A cohort study. *J Hum Hypertens* 1991 Jun; 5(3): 189-92[[Medline](#)].
  - Toto RD, Mitchell HC, Smith RD, et al: "Strict" blood pressure control and progression of disease in hypertensive nephrosclerosis. *Kidney Int* 1995 Sep; 48(3): 851-9[[Medline](#)].
  - Tracy RE, Ishii T: What is 'nephrosclerosis'? lessons from the US, Japan, and Mexico. *N Engl J Med* 2000 Sep; 343(12): 1357-66[[Medline](#)].
  - Tracy RE, Guzman MA, Oalman MC, et al: Nephrosclerosis in three cohorts of black men born 1925 to 1944, 1934 to 1953, and 1943 to 1962. *Am J Hypertens* 1993 Mar; 6(3): 185-92[[Medline](#)].
  - Tuomilehto J, Rastenyte D, Birkenhäger WH, et al: Effects of calcium-channel blockade in patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Group Investigators. *N Engl J Med* 1999 Mar 4; 340(9): 677-84[[Medline](#)].
  - Ueda S, Elliott HL, Morton JJ, Connell JM: Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. *Hypertension* 1995 Jun; 25(6): 1266-9[[Medline](#)].
  - US Renal Data System: USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2003[[Full Text](#)].
  - Walker WG, Neaton JD, Cutler JA, et al: Renal function change in hypertensive member of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. *JAMA* 1992 Dec 2; 268(21): 3085-91[[Medline](#)].
  - Weisstuch JM, Dworkin LD: Does essential hypertension cause end-stage renal disease? *Kidney Int Suppl* 1992 May; 36: S33-7[[Medline](#)].
  - Whelton PK, Klag MJ: Hypertension as a risk factor for renal disease. Review of clinical

epidemiological evidence. Hypertension 1989 May; 13(5 Suppl): 119-27[[Medline](#)].

- Whittle JC, Whelton PK, Seidler AJ, Klag MJ: Does racial variation in risk factors explain white differences in the incidence of hypertensive end-stage renal disease? Arch Intern Med 1997 Jul; 151(7): 1359-64[[Medline](#)].
- Wright JT, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288(19): 2421-31[[Medline](#)].
- Yamada T, Ishihara M, Ichikawa K, Hiramatsu K: Proteinuria and renal function during antihypertensive treatment for essential hypertension. J Am Geriatr Soc 1980 Mar; 28(3) [Medline].
- Yoshida H, Mitarai T, Kawamura T, et al: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. Clin Invest 1995 Nov; 96(5): 2162-9[[Medline](#)].
- Young JH, Klag MJ, Muntner P, et al: Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 2002 Nov; 13(12): 2776-82[[Medline](#)].
- Zarif L, Covic A, Iyengar S, et al: Inaccuracy of clinical phenotyping parameters for hyperphosphatemia in nephrosclerosis. Nephrol Dial Transplant 2000 Nov; 15(11): 1801-7[[Medline](#)].
- Zuccalà A, Zucchelli P: A renal disease frequently found at postmortem, but rarely diagnosed in vivo. Nephrol Dial Transplant 1997 Aug; 12(8): 1762-7[[Medline](#)].
- Zuccalà A, Zucchelli P: Is nephroangiosclerosis a hypertension-induced nephropathy? (Abstract). Nephrol 1996; 119: 110-4[[Medline](#)].
- Zucchelli P, Zuccalà A: Recent data on hypertension and progressive renal disease. J Hypertens 1996 Oct; 10(10): 679-82[[Medline](#)].
- Zucchelli P, Zuccalà A: The diagnostic dilemma of hypertensive nephrosclerosis: the new view. Am J Kidney Dis 1993 May; 21(5 Suppl 2): 87-91[[Medline](#)].
- Zucchelli P, Zuccalà A: Progression of renal failure and hypertensive nephrosclerosis. Kidney Int 1998 Dec; 68: S55-9[[Medline](#)].

**NOTE:**

Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted with standards at the time of publication. However, as medical science is constantly changing and **human error is always possible**, the authors, editors, or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. **FULL DISCLAIMER**

[Nephrosclerosis excerpt](#)

© Copyright 2005, eMedicine.com, Inc.

[About Us](#) | [Privacy](#) | [Terms of Use](#) | [Contact Us](#) | [Advertise](#) | [Institutional Subscribers](#)

*Original Article***Renal vascular changes in renal disease independent of hypertension**

Willem Jan W. Bos<sup>1,3</sup>, Mustafa M. Demircan<sup>1</sup>, Jan J. Weening<sup>2</sup>, Raymond T. Krediet<sup>1</sup> and Allard C. van der Wal<sup>2</sup>

Departments of <sup>1</sup>Nephrology and <sup>2</sup>Pathology, Academic Medical Center, Amsterdam, and

<sup>3</sup>Department of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands

**Abstract**

**Introduction.** Cardiovascular disease is common in patients with renal disease, but little is known about the effect of renal disease and loss of renal function on vascular morphology. Intima proliferation of small renal arteries, which correlates with atherosclerosis in the aorta, is sometimes present in renal disease and has been shown to increase with age and hypertension. We studied the effect of chronic renal disease and renal function, independent of hypertension, on intima proliferation.

**Methods.** We retrospectively selected renal biopsies of subjects in whom a glomerular filtration rate (GFR) measurement with [<sup>125</sup>I] iothalamate had been performed. To separate the effects of renal disease and renal function, we selected biopsies from (A) normotensive controls undergoing nephrectomy because of renal carcinomas; (B) normotensive patients with renal disease and GFR > 90 ml/min; (C) normotensive patients with GFR 30–90 ml/min, and (D) hypertensive patients with a GFR < 90 ml/min. The area of the arteriolar lumen, intima, and media were measured.

**Results.** No significant changes from control subjects were observed in group B. Intima proliferation was observed when renal function declined (intima/total vessel surface ratio was  $0.262 \pm 0.071$  in group C,  $0.192 \pm 0.032$  in group A, and  $0.205 \pm 0.035$  in group B,  $P < 0.05$ ). The intima proliferation was aggravated in patients with renal insufficiency and hypertension ( $0.333 \pm 0.121$ ,  $P < 0.05$ ). Media surface area was not different between groups.

**Conclusion.** Renal disease with preserved GFR does not cause significant intima proliferation of small renal arteries. Loss of renal function is accompanied by intima proliferation, even in the absence of systemic hypertension.

**Keywords:** arteries; blood pressure; cardiovascular system; hypertension; kidney failure (chronic); pathology

**Introduction**

Cardiovascular disease is very common in patients with end stage renal disease. Accelerated arterial stiffening and a high prevalence of atherosclerotic lesions contribute to high cardiovascular mortality rates in this population [1–5]. Although relatively little is known about the nature of the vascular changes in earlier stages of renal disease, there appears to be an association with several distinct pathological conditions. Intima proliferation of small renal arteries increases with age [6], and correlates with the extent of atherosclerosis in the aorta and coronary arteries [7]. Intima proliferation of small intrarenal arteries occurs at an accelerated rate in subjects with hypertension and in smokers [6,8]. It has also been observed in patients with renal disease, particularly in patients with IgA nephropathy, with or without hypertension [9–11]. Hypertension is generally considered to play an important role in the pathogenesis of intrarenal vascular changes in patients with renal disease.

The aim of the present study was to separate the effects of renal disease, renal function, and hypertension on vascular pathology of small renal arteries. We therefore compared the renal microvasculature in renal biopsies taken from selected patient groups. Selection was based on the presence of chronic renal disease, on glomerular filtration rate, and on the presence or absence of hypertension.

**Subjects and methods***Subjects*

We retrospectively analysed renal tissue of patients in whom both a renal biopsy and a [<sup>125</sup>I] iothalamate glomerular

Correspondence and offprint requests to: W. J. W. Bos MD PhD, Department of Internal Medicine, St Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, The Netherlands.

filtration rate (GFR) measurement had been performed between 1985 and 1999. Subjects with acute renal failure or any type of vasculitis were excluded. Age, diagnosis, GFR, blood pressure level, antihypertensive medication, smoking habits and, if available, total cholesterol levels at the time of the renal biopsy were collected from the patient files.

Four groups were selected:

- (A) Normotensive patients in whom nephrectomy was performed, in most cases because of a renal cell carcinoma. In those subjects, no GFR measurement was available.
- (B) Patients with chronic renal disease, having a GFR >90 ml/min, without hypertension, (blood pressure <160/90 mmHg, without the use of antihypertensive medication).
- (C) Patients with chronic renal disease, without hypertension and a GFR between 30 and 90 ml/min.
- (D) Patients with chronic renal disease, and a GFR <90 ml/min, in the presence of hypertension (blood pressure  $\geq$ 160/90 mmHg, and/or the use of one or more antihypertensive medications).

#### Processing of biopsies and morphometry

Paraffin-embedded renal biopsies of all patients included in the study (two tissue samples per patient, groups B, C, D) and tissue blocks containing normal renal parenchyma (group A) were retrieved from the files of the Department of Pathology, Academic Medical Center (AMC). Three-micrometre sections were cut and stained with elastic van Gieson (EvG) and haematoxylin and eosin (H&E) respectively.

For morphometrical analysis, cross-sectional areas of the entire artery (total surface), lumen, intima and media were planometrically quantified in EvG-stained sections using TIM image analysis software on a PC provided with a VS-100-AT frame grabber (Data Measuring Systems, Breda, the Netherlands). Sections were projected on a video screen and the inner border of the intima, the internal elastic lamina (IEL), and the outer border of the vessel (media) were outlined manually. The cross-sectional area of the intima was represented by the surface area enclosed within the inner border of the intima and the IEL. The cross-sectional area of the media was defined as the area enclosed within the IEL and the outer border of the media. All areas were measured automatically, expressed in  $\mu\text{m}^2$ , and stored on disk. All arterioles and small arteries in the range from 5000 to 20 000  $\mu\text{m}^2$  were included in the study. Of these

vessels the wall/lumen, lumen/total surface, wall/total surface, intima/total surface, and media/total surface ratios were calculated.

#### Statistical analysis

Results are expressed as means  $\pm$  SD. Paired *t*-tests were used to compare results of the different groups, if a one-way ANOVA had shown significant differences to be present. *P* values <0.05 were considered significant. Linear regression analysis was performed to calculate correlation coefficients.

#### Results

Basic characteristics for all four groups are given in Table 1. All subjects of group A underwent unilateral nephrectomy because of renal cell carcinoma. In group B, five subjects suffered from IgA nephropathy, three from membranous glomerulopathy, one from minimal-change glomerulopathy, and one from focal glomerulosclerosis. In group C, chronic interstitial nephritis was diagnosed in nine patients, and IgA nephropathy and minimal-change glomerulopathy in one patient each. In group D, hypertensive nephropathy was diagnosed in three subjects, IgA nephropathy in two, and mesangioproliferative glomerulopathy and membranous glomerulopathy in one patient each. In group A, no GFR measurements were available. However all subjects in this group had normal serum creatinine values.

Serum cholesterol levels were available in 17 subjects. Serum cholesterol ranged from 5.7 to 10.3 mmol/l (*n*=8) in group B, from 3.9 to 8.7 mmol/l in group C (*n*=5), and from 4.7 to 7.9 mmol/l in group D (*n*=4), with no significant differences between groups.

Histologically the intima thickening consisted of an accumulation of extracellular matrix, including thickening and multiplication of elastin lamellae, in which sparse spindle shaped cells (smooth-muscle cells) were present. There were no obvious structural differences in composition among the four groups, although the formation of concentric lamellae of elastin was most pronounced in the patients with hypertension. Representative examples are shown in Figure 1.

Table 1. Basic characteristics

Group	A Normotensive controls	B GFR >90, normotensive	C GFR 30–90, normotensive	D GFR 30–90, hypertensive
<i>n</i>	12	10	11	7
Age (years)	51 $\pm$ 14	36 $\pm$ 9	39 $\pm$ 15	43 $\pm$ 19
Male/female	9 : 3	8 : 2	7 : 4	4 : 3
GFR (ml/min)	NA	118 $\pm$ 10	50 $\pm$ 11§	48 $\pm$ 12 §
Blood pressure (mmHg)				
Systolic	127 $\pm$ 12	133 $\pm$ 13	128 $\pm$ 16	145 $\pm$ 21
Diastolic	79 $\pm$ 9	81 $\pm$ 8	79 $\pm$ 11	92 $\pm$ 16
Smokers ( <i>n</i> )	3	4	4	5

\**P* < 0.05 vs group A, §vs group B. NA, not assessed.

The total surface of the vessels studied tended to be largest in group A; the intima surface was largest in group D (Table 2). The wall-to-lumen ratio did not differ between groups A and B. The wall-to-lumen ratio was elevated both in normotensive and hypertensive patients with renal function loss (groups C and D, Table 2). The contribution of the wall area to the total surface area was clearly increased in group C and D.

This increase could be attributed to an increase of intima surface at the expense of luminal surface

(Figures 2, 3). The relative media surface was not different among the four groups (Table 2).

We found no significant correlations between age, blood pressure level, serum cholesterol levels, or smoking behaviour, and intima proliferation.

## Discussion

In this study we show that renal function loss is accompanied by intima proliferation of renal arterioles, even in the absence of hypertension. This intima proliferation is accelerated in the presence of hypertension. We further show that the mere presence of a renal disease does not cause intima proliferation.

Although we had data of a limited number of patients only, we were able to separate the effects of renal disease, renal function loss, and hypertension. Using [ $^{125}$ I] iothalamate GFR measurements, which are more precise in estimating renal function than creatinine clearance, we separated subjects with preserved renal function from those with chronic renal function loss. Since many patients with chronic renal function loss are hypertensive, it has been difficult to separate the effects of renal function loss and hypertension on intima proliferation. Selection of normotensive and hypertensive patients groups allowed us to make this distinction.

We did not observe a significant difference in intima proliferation of small renal arteries between normotensive controls (group A) and normotensive subjects with a renal disease and preserved renal function (group B). However, the age of the control group tended to be higher and the average size of the studied arteries tended to be larger in the control group. Both age [6] and artery size [12] were found to correlate positively with the extent of intima proliferation. Therefore, a small effect of the mere presence of renal disease cannot be completely excluded.

The results in group C show that chronic renal function loss is accompanied by intima proliferation of small renal arteries, even in the absence of systemic hypertension. This increased intima proliferation could not be explained by differences in age, smoking pattern, or cholesterol level. However, other factors have been shown to be involved in the pathogenesis of cardiovascular disease in renal failure. Lipid profiles become more atherogenic and oxidative stress increases, as do cytokine levels and levels of various growth-promoting substances such as angiotensin 2, endothelin, platelet-derived growth factor, and vascular endothelial growth factor [13–16]. The latter substances especially may be involved in smooth-muscle proliferation, which is often present in the expanding intima of renal arteries [11]. The increased arteriolar wall thickening in the absence of hypertension is also in agreement with studies in uraemic animals. In several studies progression, as well as treatment-induced regression, of hypertrophy of




Fig. 1. Histological samples. Representative examples of the light microscopy of small renal arteries in biopsies of patients enrolled in group A (A), group C (B) and group D (C). Elastic van Gieson stain, 175 $\times$ .

Table 2. Vascular dimensions

Group	A Normotensive controls	B GFR >90, normotensive	C GFR 30–90, normotensive	D GFR 30–90, hypertensive
Arteries in biopsy ( <i>n</i> )	2.55 ± 0.93	1.90 ± 0.99	2.09 ± 0.70	2.14 ± 0.90
Total surface (μm <sup>2</sup> )	14 086 ± 2 438	10 730 ± 3 684	10 206 ± 4 670	11 344 ± 2 319
Wall/lumen ratio	2.18 ± 0.45	2.76 ± 0.85	3.59 ± 1.51*	5.53 ± 3.45*
Lumen/total surface (%)	32.1 ± 4.6	27.8 ± 5.9	23.9 ± 7.4*	18.8 ± 8.7*§
Wall/total surface (%)	67.9 ± 4.6	72.2 ± 5.9	76.0 ± 7.4*	81.2 ± 8.7*§
Intima/total surface (%)	19.2 ± 3.2	20.5 ± 3.5	26.2 ± 7.1*§	33.3 ± 12.1*§
Media/total surface (%)	48.8 ± 5.5	51.7 ± 7.2	49.9 ± 4.0	47.9 ± 9.1

\**P* < 0.05 vs group A, § vs group B, in *t*-test.




Fig. 2. Luminal surface. Individual luminal surface area normalized for the total surface area (lumen area/total surface area) in percentage. Group A, normotensive controls (*n* = 12); group B, normotensive renal patients with GFR >90 ml/min (*n* = 10); group C, normotensive renal patients with GFR 30–90 ml/min (*n* = 11); group D, hypertensive renal patients with GFR 30–90 ml/min (*n* = 7).




Fig. 3. Intima surface. Individual intima surface area normalized for the total surface area (intima area/total surface area) in percentage. Group A, normotensive controls (*n* = 12); group B, normotensive renal patients with GFR >90 ml/min (*n* = 10); group C, normotensive renal patients with GFR 30–90 ml/min (*n* = 11); group D, hypertensive renal patients with GFR 30–90 ml/min (*n* = 7).

cardiac arterioles was shown to be, at least in part, independent of blood pressure [16–18].

Although the increase in intima surface between groups C and D did not reach statistical significance, there seems to be a trend towards increased intima proliferation in hypertensive patients with chronic renal function loss. The use of antihypertensive medication might have affected the intima proliferation in group D. We did not observe an age-dependent increase of the intima surface within the control group, possibly because normotensive subjects were selected. Blood pressure, which increases with age, is more strongly related to intima proliferation than to age [19]. The relatively small sample size of the control group might be another reason why no age-dependent intima proliferation was found.

Media hypertrophy was not found, even in hypertensive subjects. This is in agreement with previous findings in hypertensive rats. Whereas hypertension causes media hypertrophy in other organs, this is not necessarily the case in small renal arteries [20]. Furthermore, arterial remodelling has mainly been shown in arteries that were slightly larger (100–200 μm

diameter) [21], than most of the small arteries investigated in the present study. In the hypertensive subjects (group D), the lack of media hypertrophy might be partly explained by the use of antihypertensive agents.

### Limitations

The number of normotensive patients in whom both a renal biopsy and a GFR measurement had been performed was limited. Therefore we could not make a distinction between subjects with mild, moderate, and severe renal function loss. However, the main finding of this study, the fact that renal disease with preserved GFR does not cause intima proliferation of small renal arteries, was based on the comparison of the two largest groups, the normotensive controls (group A, *n* = 12) vs group B normotensive renal patients with GFR >90 ml/min (*n* = 10). Testing the significance of the 1.3% difference in intima surface between these groups with a power of 0.8 at a significance level of 0.05 requires a study in which 128 subjects would have to be included in both groups! Although based on



relatively small groups, we think our data provide a strong indication that intima proliferation is not accelerated in normotensive renal patients with a preserved GFR.

The study population is too small to study the effect of individual renal diseases. Furthermore, it cannot be concluded that the increase in intima proliferation observed in group C, the normotensive subjects with decreased GFR, in comparison with group B, the normotensive renal patients with preserved GFR is solely due to the difference in renal function. The fact that group B consisted completely of patients with glomerulopathies, whereas the majority of group C suffered from interstitial nephritis, might have affected our results as well.

We do not think that the use of different sampling techniques (tissue samples obtained after nephrectomy in group A vs two transcutaneous renal biopsies in the other groups) introduced a further bias. As detailed in Table 2, the average number of vessels was only marginally larger in group A. We were aware of the risk of studying larger vessels in the groups in which larger tissue specimens were available (group A). By limiting our study to vessels with a total surface area less than  $20\,000\ \mu\text{m}^2$ , such differences could be prevented.

We conclude that renal disease with preserved GFR does not cause significant intima proliferation of small renal arteries. However, once associated with a loss of renal function, renal disease appears to be accompanied by intimal proliferations, even in the absence of systemic hypertension.

**Acknowledgements.** W. J. W. Bos is the recipient of grant 902-18-307 of the Netherlands Foundation for Scientific Research (NWO).

## References

1. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients. *Semin Dial* 1999; 12: 69-76
2. Foley RN, Parfrey PS, Sarnak M. The clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998; 32 [Suppl.]: S112-115
3. Parfrey PS, Foley RN, Harnett JD. Organ and metabolic complications: cardiac. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF, eds. *Replacement of Renal Function by Dialysis*. Kluwer, Dordrecht, 1996, 990-1002
4. London GM, Guerin AP, Marchais SJ *et al.* Cardiac and arterial interactions in end-stage renal disease. *Kidney Int* 1996; 50: 600-608
5. London GM, Guerin AP, Marchais SJ. Hemodynamic overload in end-stage renal disease patients. *Semin Dial* 1999; 12: 77-83
6. Tracey RE, Berenson G, Wattigney W, Barrett TJ. The evolution of benign arterionephrosclerosis from age 6 to 70. *Am J Pathol* 1990; 136: 429-439
7. Tracey RE, Strong JP, Newman WP, Malcolm GT, Oalman MC, Guzman MA. Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years. *Kidney Int* 1996; 49: 564-570
8. Black HR, Zeevi GR, Silten RM, Smith GJW. Effect of heavy cigarette smoking on renal and myocardial arterioles. *Nephron* 1983; 34: 173-179
9. Clarkson AR, Seymour AE, Thompson AJ, Haynes WDG, Chan YL, Jackson B. IgA nephropathy: a syndrome of uniform morphology, diverse clinical features and uncertain prognosis. *Clin Nephrol* 1977; 8: 459-471
10. Feiner HD, Cabili S, Baldwin DS, Schacht RG, Gallo GR. Intrarenal vascular sclerosis in IgA nephropathy. *Clin Nephrol* 1982; 18: 183-192
11. Helmchen U. Effects of hypertension on renal vasculature and structure. In: Cameron S, Davison AM, Gruenfeld JP, Kerr D, Ritz E, eds. *Oxford Textbook of Clinical Nephrology*, Oxford University Press, Oxford, 1992, 2075-2083
12. Tracey RE, Mercante DE, Moncada A, Berenson G. Quantitation of hypertensive nephrosclerosis on an objective rational scale of measure in adults and children. *Am J Clin Pathol* 1986; 85: 312-318
13. Prichard S. Dyslipidemia as a risk factor for cardiac disease in dialysis patients. *Semin Dial* 1999; 12: 87-90
14. Rigatto C, Singal PK. Oxidative stress in uremia: impact on cardiac disease in dialysis patients. *Semin Dial* 1999; 12: 91-96
15. Amann K, Ritz E. Cardiovascular abnormalities in ageing and in uraemia—only analogy or shared pathomechanisms? *Nephrol Dial Transplant* 1998; 13 [Suppl. 7]: 6-11
16. Amann K, Kronenberg G, Gehlen F *et al.* Cardiac remodelling in experimental renal failure—an immunohistochemical study. *Nephrol Dial Transplant* 1998; 13: 1958-1966
17. Tornig J, Gross ML, Simonaviciene A, Mall G, Ritz E, Amann K. Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. *Am Soc Nephrol* 1999; 10: 77-83
18. Nabokov AV, Amann K, Wessels S, Munter K, Wagner J, Ritz E. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. *Kidney Int* 1999; 55: 512-519
19. Tracey RE, Velez-Duran M, Heigle T, Oalman MC. Two variants of nephrosclerosis separately related to age and blood pressure. *Am J Pathol* 1988; 131: 270-282
20. Skov K, Fenger-Gron J, Mulvany MJ. Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and an endothelin receptor antagonist on renal afferent arteriolar structure. *Hypertension* 1996; 28: 464-471
21. Mulvany MJ. Resistance vessel structure and the pathogenesis of hypertension. *J Hypertens* 1993; 11 [Suppl 5]: S7-12

Received for publication: 14.3.00

Accepted in revised form: 10.10.00

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**